Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine 1978 - 1979
  • M.D., The University of Chicago 1978
• 

  Previous Appointments & Affiliations

  • Chief, Division of Medical Oncology, Medicine, Medical Oncology, Medicine 2013 - 2021
  • Charles Johnson, M.D. Distinguished Professor of Medicine, Medicine, Medical Oncology, Medicine 2016 - 2017
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2015
• Recognition
• 

  In the News

  • JAN 11, 2023

    Duke Cancer Institute

    In Search of Early Diagnosis of Pancreatic Cancer

  • MAY 5, 2016

    Duke Awards Distinguished Professorships, Inducts New Bass Society Members

  • AUG 13, 2015

    The New York Times

    Dr. James Abbruzzese quoted: Former President Jimmy Carter says he has cancer
• Expertise
• 

  Subject Headings

  • Adolescent
  • Adult
  • Age Distribution
  • Albumins
  • Animals
  • Blood Transfusion
  • Cell Differentiation
  • Cell Growth Processes
  • Cell Lineage
  • Cell Movement
  • Cell Transformation, Neoplastic
  • Chemotherapy, Adjuvant
  • Chi-Square Distribution
  • Child
  • Cisplatin
  • Clinical Competence
  • Combined Modality Therapy
  • Cytokines
  • DNA Repair
  • Diabetes Complications
  • Diabetes Mellitus, Type 2
  • Diagnosis, Differential
  • Disease Models, Animal
  • Disease-Free Survival
  • Drug Delivery Systems
  • Drug Therapy, Combination
  • Dyspnea
  • Epithelial Cells
  • False Positive Reactions
  • Fibrosis
  • Genetic Variation
  • Genotype
  • HEK293 Cells
  • HT29 Cells
  • Health Status
  • Homozygote
  • Hypothyroidism
  • Immunohistochemistry
  • Inflammation
  • Intercellular Signaling Peptides and Proteins
  • Islets of Langerhans
  • Isotope Labeling
  • Liver
  • Liver Neoplasms
  • Liver Neoplasms, Experimental
  • Lymph Nodes
  • Membrane Proteins
  • Mesoderm
  • Models, Biological
  • Mutation
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Proteins
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Neoplasms
  • Nervous System
  • Odds Ratio
  • Organoplatinum Compounds
  • Oxidative Stress
  • Pain
  • Pancreas
  • Pancreatectomy
  • Pancreatic Ducts
  • Pancreatic Neoplasms
  • Pancreaticoduodenectomy
  • Patient Care Team
  • Phenotype
  • Physicians
  • Polymorphism, Genetic
  • Probability
  • Prognosis
  • Proteolysis
  • Pyrimidines
  • Quinazolines
  • Radiation Tolerance
  • Radiotherapy, Adjuvant
  • Reactive Oxygen Species
  • Reference Values
  • Reproducibility of Results
  • Risk
  • Sensitivity and Specificity
  • Sepsis
  • Sex Distribution
  • Signal Transduction
  • Thiazoles
  • Time Factors
  • Treatment Outcome
  • Tumor Cells, Cultured
  • Tumor Markers, Biological
  • Water
  • Xenograft Model Antitumor Assays
• Research
• 

  Selected Grants

  • A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors awarded by Amgen, Inc. 2022 - 2027
  • A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS awarded by Pfizer, Inc. 2021 - 2026
  • Pfizer - C4201002 - PF-07265807 awarded by Pfizer, Inc. 2020 - 2025
  • Adapting K-MDS to detect KRAS-mutant ctDNA awarded by National Institutes of Health 2022 - 2025
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2023
  • Cancer Therapy Evaluation Program Administrative Agreement awarded by Leidos Biomedical Research, Inc. 2022
  • 3D Biology Signatures defined by Nanostring Max System awarded by North Carolina Biotechnology Center 2018 - 2019
  • Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer awarded by Department of Defense 2016 - 2017
  • Topic Refinement, Task order 9 Topic Briefs awarded by Patient Centered Outcomes Research Institute 2016
• 

  External Relationships

  • American Association for Cancer Research
  • Amgen, Inc.
  • AstraZeneca
  • Bessor Pharma
  • Case Western Reserve University
  • FujiFilm
  • Lustgarten Foundation
  • Moleculin Biotech Inc.
  • Panbela Therapeutics
  • Pancreatic Cancer Action Network
  • Pancreatic Cancer United Kingdom
  • Pfizer Inc.
  • The Trustees of Columbia University
  • The University of North Carolina at Chapel Hill
  • University of California San Diego
  • University of Nebraska Medical Center
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Neoptolemos, J. P., R. Urrutia, J. L. Abbruzzese, and M. W. Büchler. Preface, 2018. https://doi.org/10.1007/978-1-4939-7193-0.
       Full Text

  • Academic Articles

    • Zhu, Liang, Juntao Ji, Jianjia Ma, Dan Wang, Muyun Liu, James Xianxing Du, Rong Chen, et al. “Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma.” Cancers (Basel) 14, no. 11 (May 31, 2022). https://doi.org/10.3390/cancers14112723.
       Full Text  Open Access Copy  Link to Item
    • Schoenfeld, Jonathan D., Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z. Kao, Ana Lako, Junko Tsuji, Yang Liu, et al. “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.” Lancet Oncol 23, no. 2 (February 2022): 279–91. https://doi.org/10.1016/S1470-2045(21)00658-6.
       Full Text  Link to Item
    • Moschos, Stergios J., Zeynep Eroglu, Nikhil I. Khushalani, Kari L. Kendra, George Ansstas, Gino K. In, Peng Wang, et al. “Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).” Melanoma Res 31, no. 2 (April 1, 2021): 162–72. https://doi.org/10.1097/CMR.0000000000000726.
       Full Text  Link to Item
    • Liu, Muyun, Dan Wang, Yongde Luo, Lianghao Hu, Yawei Bi, Juntao Ji, Haojie Huang, et al. “Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.” Cell Death Dis 12, no. 2 (February 16, 2021): 189. https://doi.org/10.1038/s41419-021-03473-6.
       Full Text  Link to Item
    • Luo, Yongde, Xiaokun Li, Jianjia Ma, James L. Abbruzzese, and Weiqin Lu. “Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.” Cancers (Basel) 13, no. 4 (February 13, 2021). https://doi.org/10.3390/cancers13040778.
       Full Text  Link to Item
    • DeVito, Nicholas C., Colm Kelleher, Kyle C. Strickland, James Abbruzzese, Carey Anders, Brent A. Hanks, Jingquan Jia, et al. “A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis.” Ame Case Rep 5 (2021): 14. https://doi.org/10.21037/acr-20-154.
       Full Text  Link to Item
    • Green, Michelle F., Jonathan L. Bell, Christopher B. Hubbard, Shannon J. McCall, Matthew S. McKinney, Jinny E. Riedel, Carolyn S. Menendez, James L. Abbruzzese, John H. Strickler, and Michael B. Datto. “Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.” Jco Precis Oncol 5 (2021). https://doi.org/10.1200/PO.21.00030.
       Full Text  Link to Item
    • Turner, Megan C., Sabran J. Masoud, Marcelo Cerullo, Mohamed A. Adam, Kevin N. Shah, Dan G. Blazer, James L. Abbruzzese, and Sabino Zani. “Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.” Hpb (Oxford) 22, no. 11 (November 2020): 1542–48. https://doi.org/10.1016/j.hpb.2020.03.006.
       Full Text  Link to Item
    • Liu, Xiaowen, Danwen Qian, Hongliang Liu, James L. Abbruzzese, Sheng Luo, Kyle M. Walsh, and Qingyi Wei. “Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer.” Mol Carcinog 59, no. 8 (August 2020): 930–39. https://doi.org/10.1002/mc.23208.
       Full Text  Open Access Copy  Link to Item
    • Luo, Yongde, Yaying Yang, Muyun Liu, Dan Wang, Feng Wang, Yawei Bi, Juntao Ji, et al. “Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.” Gastroenterology 157, no. 5 (November 2019): 1413-1428.e11. https://doi.org/10.1053/j.gastro.2019.07.030.
       Full Text  Link to Item
    • Xu, Xinyuan, Danwen Qian, Hongliang Liu, Diana Cruz, Sheng Luo, Kyle M. Walsh, James L. Abbruzzese, Xuefeng Zhang, and Qingyi Wei. “Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk.” Mol Carcinog 58, no. 8 (August 2019): 1338–48. https://doi.org/10.1002/mc.23018.
       Full Text  Open Access Copy  Link to Item
    • Feng, Yun, Hongliang Liu, Bensong Duan, Zhensheng Liu, James Abbruzzese, Kyle M. Walsh, Xuefeng Zhang, and Qingyi Wei. “Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.” Carcinogenesis 40, no. 4 (June 10, 2019): 521–28. https://doi.org/10.1093/carcin/bgz029.
       Full Text  Open Access Copy  Link to Item
    • Yang, Wenjun, Hongliang Liu, Bensong Duan, Xinyuan Xu, Dennis Carmody, Sheng Luo, Kyle M. Walsh, et al. “Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk.” Cancer Sci 110, no. 6 (June 2019): 2022–32. https://doi.org/10.1111/cas.14017.
       Full Text  Open Access Copy  Link to Item
    • Wang, Dan, Yawei Bi, Lianghao Hu, Yongde Luo, Juntao Ji, Albert Z. Mao, Craig D. Logsdon, et al. “Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS.” Cell Commun Signal 17, no. 1 (February 28, 2019): 19. https://doi.org/10.1186/s12964-019-0333-7.
       Full Text  Link to Item
    • Luo, Yongde, Dan Wang, James L. Abbruzzese, and Weiqin Lu. “Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.” Methods Mol Biol 1882 (2019): 207–19. https://doi.org/10.1007/978-1-4939-8879-2_19.
       Full Text  Link to Item
    • Safe, Stephen, James Abbruzzese, Maen Abdelrahim, and Erik Hedrick. “Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.” Cancer Prev Res (Phila) 11, no. 7 (July 2018): 371–82. https://doi.org/10.1158/1940-6207.CAPR-17-0407.
       Full Text  Link to Item
    • Duan, Bensong, Jiangfeng Hu, Hongliang Liu, Yanru Wang, Hongyu Li, Shun Liu, Jichun Xie, et al. “Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.” Int J Cancer 142, no. 7 (April 1, 2018): 1322–31. https://doi.org/10.1002/ijc.31171.
       Full Text  Open Access Copy  Link to Item
    • Abbruzzese, James L., Dana K. Andersen, Carl A. K. Borrebaeck, Suresh T. Chari, Eithne Costello, Zobeida Cruz-Monserrate, Guido Eibl, et al. “The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.” Pancreas 47, no. 5 (2018): 516–25. https://doi.org/10.1097/MPA.0000000000001037.
       Full Text  Link to Item
    • Berlin, Jordan D., Yang Feng, Paul Catalano, James L. Abbruzzese, Philip A. Philip, Robert R. McWilliams, Andrew M. Lowy, Al B. Benson, and A William Blackstock. “An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).” Oncology 94, no. 1 (2018): 39–46. https://doi.org/10.1159/000480295.
       Full Text  Link to Item
    • Andersen, Dana K., Murray Korc, Gloria M. Petersen, Guido Eibl, Donghui Li, Michael R. Rickels, Suresh T. Chari, and James L. Abbruzzese. “Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer.” Diabetes 66, no. 5 (May 2017): 1103–10. https://doi.org/10.2337/db16-1477.
       Full Text  Link to Item
    • Capello, Michela, Leonidas E. Bantis, Ghislaine Scelo, Yang Zhao, Peng Li, Dilsher S. Dhillon, Nikul J. Patel, et al. “Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.” J Natl Cancer Inst 109, no. 4 (April 2017). https://doi.org/10.1093/jnci/djw266.
       Full Text  Link to Item
    • Capello, Michela, Leonidas E. Bantis, Ghislaine Scelo, Yang Zhao, Peng Li, Dilsher S. Dhillon, Nikul J. Patel, et al. “Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.” J Natl Cancer Inst 109, no. 4 (April 1, 2017). https://doi.org/10.1093/jnci/djw266.
       Full Text  Link to Item
    • Cloyd, Jordan M., Matthew H. G. Katz, Laura Prakash, Gauri R. Varadhachary, Robert A. Wolff, Rachna T. Shroff, Milind Javle, et al. “Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.” J Gastrointest Surg 21, no. 1 (January 2017): 164–74. https://doi.org/10.1007/s11605-016-3265-1.
       Full Text  Link to Item
    • Ye, Min, Weiqin Lu, Xiaojie Wang, Cong Wang, James L. Abbruzzese, Guang Liang, Xiaokun Li, and Yongde Luo. “FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.” Endocrinology 157, no. 12 (December 2016): 4754–69. https://doi.org/10.1210/en.2016-1710.
       Full Text  Link to Item
    • Palta, M., B. Czito, J. Abbruzzese, H. Uronis, E. A. Duffy, D. T. Blazer, and C. G. Willett. “Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study.” Int J Radiat Oncol Biol Phys 96, no. 2S (October 1, 2016): S204–5. https://doi.org/10.1016/j.ijrobp.2016.06.509.
       Full Text  Link to Item
    • Overman, M. J., V. Morris, B. Kee, D. Fogelman, L. Xiao, C. Eng, A. Dasari, et al. “Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.” Ann Oncol 27, no. 6 (June 2016): 1068–74. https://doi.org/10.1093/annonc/mdw073.
       Full Text  Open Access Copy  Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
       Full Text  Open Access Copy  Link to Item
    • Parsons, Henrique A., Vickie E. Baracos, David S. Hong, James Abbruzzese, Eduardo Bruera, and Razelle Kurzrock. “The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer.” Oncotarget 7, no. 15 (April 12, 2016): 20293–304. https://doi.org/10.18632/oncotarget.7773.
       Full Text  Open Access Copy  Link to Item
    • Li, Donghui, Jennifer Moughan, Christopher Crane, John P. Hoffman, William F. Regine, Ross A. Abrams, Howard Safran, et al. “RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.” Int J Radiat Oncol Biol Phys 94, no. 3 (March 1, 2016): 554–60. https://doi.org/10.1016/j.ijrobp.2015.10.062.
       Full Text  Link to Item
    • Mettu, Niharika B., and James L. Abbruzzese. “Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.” J Oncol Pract 12, no. 1 (January 2016): 17–23. https://doi.org/10.1200/JOP.2015.009092.
       Full Text  Open Access Copy  Link to Item
    • Lu, W., Y. Yang, Y. Luo, Y. Liu, X. Wang, M. Liu, R. A. Wolff, J. L. Abbruzzese, and C. D. Logsdon. “FGF21 Delays Pancreatic Cancer Formation and Prevents Liver Metastasis in Oncogenic Kras Expressing Mice Fed on High-Fat Diet.” Pancreas 44, no. 8 (November 1, 2015): 1393–1393.
       Link to Item
    • Li, Donghui, Mayurika N. Pise, Michael J. Overman, Chang Liu, Hongwei Tang, Saroj Vadhan-Raj, and James L. Abbruzzese. “ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer.” Cancer Med 4, no. 11 (November 2015): 1651–58. https://doi.org/10.1002/cam4.513.
       Full Text  Link to Item
    • Raghav, Kanwal Pratap Singh, Sminil Mahajan, James C. Yao, Brian P. Hobbs, Donald A. Berry, Rebecca D. Pentz, Alda Tam, et al. “From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.” J Clin Oncol 33, no. 31 (November 1, 2015): 3583–90. https://doi.org/10.1200/JCO.2015.62.4148.
       Full Text  Link to Item
    • Fogelman, David, Elizabeth A. Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, et al. “Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.” Cancer Chemother Pharmacol 76, no. 3 (September 2015): 489–98. https://doi.org/10.1007/s00280-015-2788-6.
       Full Text  Link to Item
    • Reddy, S. M., S. Kopetz, J. Morris, N. Parikh, W. Qiao, M. J. Overman, D. Fogelman, et al. “Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.” Invest New Drugs 33, no. 4 (August 2015): 977–84. https://doi.org/10.1007/s10637-015-0257-z.
       Full Text  Link to Item
    • Zhao, Jun, Chunhui Wu, James Abbruzzese, Rosa F. Hwang, and Chun Li. “Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells.” Mol Pharm 12, no. 6 (June 1, 2015): 2093–2100. https://doi.org/10.1021/mp500875f.
       Full Text  Link to Item
    • Li, D., Y. Mao, P. Chang, C. Liu, M. M. Hassan, S. J. Yeung, and J. L. Abbruzzese. “Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer.” American Journal of Cancer Research 5, no. 10 (January 1, 2015): 3260–69.
    • Koay, Eugene J., Flavio E. Baio, Alexander Ondari, Mark J. Truty, Vittorio Cristini, Ryan M. Thomas, Rong Chen, et al. “Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.” Phys Biol 11, no. 6 (November 26, 2014): 065002. https://doi.org/10.1088/1478-3975/11/6/065002.
       Full Text  Link to Item
    • Wang, H., J. S. Estrella, D. Chatterjee, M. H. Katz, A. Rashid, R. A. Wolff, G. R. Varadhachary, et al. “Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.” Pathology 46 Suppl 2 (October 2014): S25. https://doi.org/10.1097/01.PAT.0000454135.19954.47.
       Full Text  Link to Item
    • Abbruzzese, James L., and Kenneth R. Hess. “New option for the initial management of metastatic pancreatic cancer?” J Clin Oncol 32, no. 23 (August 10, 2014): 2405–7. https://doi.org/10.1200/JCO.2013.54.4155.
       Full Text  Link to Item
    • Kaseb, Ahmed O., Lianchun Xiao, Manal M. Hassan, Young Kwang Chae, Ju-Seog Lee, Jean-Nicolas Vauthey, Sunil Krishnan, et al. “Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.” J Natl Cancer Inst 106, no. 5 (May 9, 2014). https://doi.org/10.1093/jnci/dju088.
       Full Text  Link to Item
    • Guo, Rongjun, Michael Overman, Deyali Chatterjee, Asif Rashid, Stuti Shroff, Hua Wang, Matthew H. Katz, et al. “Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.” Hum Pathol 45, no. 5 (May 2014): 1015–23. https://doi.org/10.1016/j.humpath.2013.12.016.
       Full Text  Link to Item
    • Koay, Eugene J., Mark J. Truty, Vittorio Cristini, Ryan M. Thomas, Rong Chen, Deyali Chatterjee, Ya’an Kang, et al. “Transport properties of pancreatic cancer describe gemcitabine delivery and response.” J Clin Invest 124, no. 4 (April 2014): 1525–36. https://doi.org/10.1172/JCI73455.
       Full Text  Link to Item
    • Shroff, Stuti, Asif Rashid, Hua Wang, Matthew H. Katz, James L. Abbruzzese, Jason B. Fleming, and Huamin Wang. “SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.” Hum Pathol 45, no. 3 (March 2014): 456–63. https://doi.org/10.1016/j.humpath.2013.10.008.
       Full Text  Link to Item
    • Wang, Hua, Yue Chen, Ping Lin, Lei Li, Guisheng Zhou, Guangchao Liu, Craig Logsdon, et al. “The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1.” J Biol Chem 289, no. 7 (February 14, 2014): 4009–17. https://doi.org/10.1074/jbc.M113.520106.
       Full Text  Link to Item
    • Estrella, Jeannelyn S., Lei Li, Asif Rashid, Hua Wang, Matthew H. Katz, Jason B. Fleming, James L. Abbruzzese, and Huamin Wang. “Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution.” Am J Surg Pathol 38, no. 2 (February 2014): 147–57. https://doi.org/10.1097/PAS.0000000000000141.
       Full Text  Link to Item
    • Fisch, Michael J., James L. Abbruzzese, and Waun K. Hong. “Evaluating physician performance in oncology: moneyball becomes impactball.” J Oncol Pract 10, no. 1 (January 2014): 79–81. https://doi.org/10.1200/JOP.2013.001218.
       Full Text  Link to Item
    • Kaseb, A. O., L. Xiao, M. M. Hassan, Y. K. Chae, J. S. Lee, J. N. Vauthey, S. Krishnan, et al. “Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.” Journal of the National Cancer Institute 106, no. 5 (January 1, 2014).
    • Kaseb, Ahmed O., Neeraj N. Shah, Hesham M. Hassabo, Jeffrey S. Morris, Lianchun Xiao, Yasmin M. Abaza, Khalid Soliman, et al. “Reassessing hepatocellular carcinoma staging in a changing patient population.” Oncology 86, no. 2 (2014): 63–71. https://doi.org/10.1159/000356573.
       Full Text  Link to Item
    • Tzeng, Ching-Wei D., Hop S. Tran Cao, Jeffrey E. Lee, Peter W. T. Pisters, Gauri R. Varadhachary, Robert A. Wolff, James L. Abbruzzese, et al. “Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.” J Gastrointest Surg 18, no. 1 (January 2014): 16–24. https://doi.org/10.1007/s11605-013-2412-1.
       Full Text  Link to Item
    • Tzeng, Ching-Wei D., Matthew H. G. Katz, Jason B. Fleming, Jeffrey E. Lee, Peter W. T. Pisters, Holly M. Holmes, Gauri R. Varadhachary, et al. “Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.” J Gastrointest Surg 18, no. 1 (January 2014): 146–55. https://doi.org/10.1007/s11605-013-2371-6.
       Full Text  Link to Item
    • Chatterjee, Deyali, Matthew H. Katz, Asif Rashid, Jeannelyn S. Estrella, Hua Wang, Gauri R. Varadhachary, Robert A. Wolff, et al. “Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.” Histopathology 63, no. 6 (December 2013): 841–51. https://doi.org/10.1111/his.12234.
       Full Text  Link to Item
    • Abbott, Daniel E., Ching-Wei David Tzeng, Ryan P. Merkow, Scott B. Cantor, George J. Chang, Matthew Harold Katz, David J. Bentrem, et al. “The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.” Ann Surg Oncol 20 Suppl 3 (December 2013): S500–508. https://doi.org/10.1245/s10434-013-2882-0.
       Full Text  Link to Item
    • Zenali, Maryam, Michael J. Overman, Asif Rashid, Russell B. Broaddus, Hua Wang, Matthew H. Katz, Jason B. Fleming, James L. Abbruzzese, and Huamin Wang. “Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.” Hum Pathol 44, no. 12 (December 2013): 2792–98. https://doi.org/10.1016/j.humpath.2013.07.030.
       Full Text  Link to Item
    • Luo, Yongde, Chaofeng Yang, Min Ye, Chengliu Jin, James L. Abbruzzese, Mong-Hong Lee, Sai-Ching J. Yeung, and Wallace L. McKeehan. “Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.” Cancer Metab 1, no. 1 (November 25, 2013): 21. https://doi.org/10.1186/2049-3002-1-21.
       Full Text  Link to Item
    • Shroff, Stuti, Michael J. Overman, Asif Rashid, Rachna T. Shroff, Hua Wang, Deyali Chatterjee, Matthew H. Katz, et al. “The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.” Arch Pathol Lab Med 137, no. 11 (November 2013): 1619–26. https://doi.org/10.5858/arpa.2012-0418-OA.
       Full Text  Link to Item
    • Stuti, S., S. Shroff, M. J. Overman, A. Rashid, R. T. Shroff, H. Wang, D. Chatterjee, et al. “The expression of pten is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.” Archives of Pathology and Laboratory Medicine 137, no. 11 (November 1, 2013): 1619–26. https://doi.org/10.5858/arpa.2012-0418-OA).
       Full Text
    • Hassan, Manal M., Ahmed Kaseb, Carol J. Etzel, Hashem El-Serag, Margaret R. Spitz, Ping Chang, Katherine S. Hale, et al. “Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.” Mol Carcinog 52 Suppl 1, no. 0 (November 2013): E139–47. https://doi.org/10.1002/mc.22057.
       Full Text  Link to Item
    • Khalil, Mohamed A., Wei Qiao, Peter Carlson, Binsah George, Milind Javle, Michael Overman, Gauri Varadhachary, Robert A. Wolff, James L. Abbruzzese, and David R. Fogelman. “The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.” Invest New Drugs 31, no. 5 (October 2013): 1375–83. https://doi.org/10.1007/s10637-013-9967-2.
       Full Text  Link to Item
    • Kaseb, Ahmed O., Junichi Shindoh, Yehuda Z. Patt, Robert E. Roses, Giuseppe Zimmitti, Richard D. Lozano, Manal M. Hassan, et al. “Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.” Cancer 119, no. 18 (September 15, 2013): 3334–42. https://doi.org/10.1002/cncr.28209.
       Full Text  Link to Item
    • Overman, M. J., J. Zhang, S. Kopetz, M. Davies, Z. Q. Jiang, K. Stemke-Hale, P. Rümmele, et al. “Erratum: Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome (PLoS ONE (2013) 8:7 DOI: 10.1371/annotation/6afdd046- e1a7-4421-b7ec-0c9492ce2544).” Plos One 8, no. 7 (July 3, 2013). https://doi.org/10.1371/annotation/6afdd046-e1a7-4421-b7ec-0c9492ce2544.
       Full Text
    • Tzeng, Ching-Wei D., Daniel E. Abbott, Scott B. Cantor, Jason B. Fleming, Jeffrey E. Lee, Peter W. T. Pisters, Gauri R. Varadhachary, et al. “Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.” Ann Surg Oncol 20, no. 7 (July 2013): 2197–2203. https://doi.org/10.1245/s10434-013-2889-6.
       Full Text  Link to Item
    • Foo, Wai Chin, Asif Rashid, Hua Wang, Matthew H. Katz, Jeffrey E. Lee, Peter W. Pisters, Robert A. Wolff, James L. Abbruzzese, Jason B. Fleming, and Huamin Wang. “Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.” Hum Pathol 44, no. 6 (June 2013): 1024–30. https://doi.org/10.1016/j.humpath.2012.09.001.
       Full Text  Link to Item
    • Chang, Zhe, Zhongkui Li, Xiaoyang Wang, Ya’an Kang, Yuhui Yuan, Jiangong Niu, Huamin Wang, et al. “Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.” Clin Cancer Res 19, no. 3 (February 1, 2013): 549–59. https://doi.org/10.1158/1078-0432.CCR-12-0032.
       Full Text  Link to Item
    • Li, Lei, Mohammad Othman, Asif Rashid, Hua Wang, Zhaoshen Li, Matthew H. Katz, Jeffrey E. Lee, et al. “Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells.” Histopathology 62, no. 3 (February 2013): 465–71. https://doi.org/10.1111/his.12023.
       Full Text  Link to Item
    • Yao, Yixin, Milind Suraokar, Bryant G. Darnay, Brett G. Hollier, Tattym E. Shaiken, Takayuki Asano, Chien-Hung Chen, et al. “BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.” Sci Signal 6, no. 257 (January 8, 2013): ra2. https://doi.org/10.1126/scisignal.2003295.
       Full Text  Link to Item
    • Kaseb, Ahmed O., Mohamed Shama, Ibrahim Halil Sahin, Ajay Nooka, Hesham M. Hassabo, Jean-Nicolas Vauthey, Thomas Aloia, et al. “Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.” Oncology 85, no. 4 (2013): 197–203. https://doi.org/10.1159/000354698.
       Full Text  Link to Item
    • Overman, Michael J., Janhavi Modak, Scott Kopetz, Ravi Murthy, James C. Yao, Marshall E. Hicks, James L. Abbruzzese, and Alda L. Tam. “Use of research biopsies in clinical trials: are risks and benefits adequately discussed?” J Clin Oncol 31, no. 1 (January 1, 2013): 17–22. https://doi.org/10.1200/JCO.2012.43.1718.
       Full Text  Link to Item
    • Overman, Michael J., Jiexin Zhang, Scott Kopetz, Michael Davies, Zhi-Qin Jiang, Katherine Stemke-Hale, Petra Rümmele, et al. “Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.” Plos One 8, no. 6 (2013): e65144. https://doi.org/10.1371/journal.pone.0065144.
       Full Text  Link to Item
    • Sahin, Ibrahim Halil, Mohamed A. Shama, Motofumi Tanaka, James L. Abbruzzese, Steven A. Curley, Manal Hassan, and Donghui Li. “Association of diabetes and perineural invasion in pancreatic cancer.” Cancer Med 1, no. 3 (December 2012): 357–62. https://doi.org/10.1002/cam4.43.
       Full Text  Link to Item
    • Katz, Matthew H. G., Jason B. Fleming, Priya Bhosale, Gauri Varadhachary, Jeffrey E. Lee, Robert Wolff, Huamin Wang, et al. “Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.” Cancer 118, no. 23 (December 1, 2012): 5749–56. https://doi.org/10.1002/cncr.27636.
       Full Text  Link to Item
    • Wang, Jiansheng, Jeannelyn S. Estrella, Lan Peng, Asif Rashid, Gauri R. Varadhachary, Hua Wang, Jeffrey E. Lee, et al. “Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.” Cancer 118, no. 15 (August 1, 2012): 3801–11. https://doi.org/10.1002/cncr.26717.
       Full Text  Link to Item
    • Weng, Shaofan, Hua Wang, Weihong Chen, Matthew H. Katz, Deyali Chatterjee, Jeffrey E. Lee, Peter W. Pisters, et al. “Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.” Cancer Epidemiol Biomarkers Prev 21, no. 8 (August 2012): 1336–43. https://doi.org/10.1158/1055-9965.EPI-12-0223.
       Full Text  Link to Item
    • Truty, Mark J., Ryan M. Thomas, Matthew H. Katz, Jean-Nicolas Vauthey, Christopher Crane, Gaury R. Varadhachary, Robert A. Wolff, James L. Abbruzzese, Jeffrey E. Lee, and Jason B. Fleming. “Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.” J Am Coll Surg 215, no. 1 (July 2012): 41–51. https://doi.org/10.1016/j.jamcollsurg.2012.03.024.
       Full Text  Link to Item
    • Chatterjee, Deyali, Matthew H. Katz, Asif Rashid, Gauri R. Varadhachary, Robert A. Wolff, Hua Wang, Jeffrey E. Lee, et al. “Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.” Cancer 118, no. 12 (June 15, 2012): 3182–90. https://doi.org/10.1002/cncr.26651.
       Full Text  Link to Item
    • Dong, Xiaoqun, Yanan Li, Ping Chang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer.” Mol Carcinog 51, no. 6 (June 2012): 491–99. https://doi.org/10.1002/mc.20817.
       Full Text  Link to Item
    • Sadeghi, Navid, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li. “Metformin use is associated with better survival of diabetic patients with pancreatic cancer.” Clin Cancer Res 18, no. 10 (May 15, 2012): 2905–12. https://doi.org/10.1158/1078-0432.CCR-11-2994.
       Full Text  Link to Item
    • Friday, Benjamin, Yvonne Lassere, Christina A. Meyers, Akira Mita, James L. Abbruzzese, and Melanie B. Thomas. “A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.” Anticancer Res 32, no. 5 (May 2012): 1689–96.
       Link to Item
    • Overman, Michael J., Chung-Yuan Hu, Scott Kopetz, James L. Abbruzzese, Robert A. Wolff, and George J. Chang. “A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.” Ann Surg Oncol 19, no. 5 (May 2012): 1439–45. https://doi.org/10.1245/s10434-011-2173-6.
       Full Text  Link to Item
    • Tomblyn, Michael B., Bryan H. Goldman, Charles R. Thomas, Jacqueline K. Benedetti, Heinz-Josef Lenz, Vivek Mehta, Thaddeus Beeker, et al. “Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).” J Thorac Oncol 7, no. 5 (May 2012): 906–12. https://doi.org/10.1097/JTO.0b013e31824c7bed.
       Full Text  Link to Item
    • Chang, David Z., Ying Ma, Baoan Ji, Yan Liu, Patrick Hwu, James L. Abbruzzese, Craig Logsdon, and Huamin Wang. “Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.” J Hematol Oncol 5 (April 4, 2012): 15. https://doi.org/10.1186/1756-8722-5-15.
       Full Text  Link to Item
    • Chatterjee, Deyali, Asif Rashid, Hua Wang, Matthew H. Katz, Robert A. Wolff, Gauri R. Varadhachary, Jeffrey E. Lee, et al. “Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.” Am J Surg Pathol 36, no. 4 (April 2012): 552–59. https://doi.org/10.1097/PAS.0b013e318240c1c0.
       Full Text  Link to Item
    • Dong, Xiaoqun, Yanan Li, Hongwei Tang, Ping Chang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer.” Cancer Epidemiol 36, no. 2 (April 2012): 206–11. https://doi.org/10.1016/j.canep.2011.05.013.
       Full Text  Link to Item
    • Kaseb, A. O., J. S. Morris, M. M. Hassan, and J. L. Abbruzzese. “Reply to A. Goyal et al.” Journal of Clinical Oncology 30, no. 9 (March 20, 2012): 1019–20. https://doi.org/10.1200/JCO.2011.40.9375.
       Full Text
    • Chatterjee, Deyali, Matthew H. Katz, Asif Rashid, Hua Wang, Alina C. Iuga, Gauri R. Varadhachary, Robert A. Wolff, et al. “Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.” Am J Surg Pathol 36, no. 3 (March 2012): 409–17. https://doi.org/10.1097/PAS.0b013e31824104c5.
       Full Text  Link to Item
    • Dakik, Hassan K., Daniel J. Moskovic, Peter J. Carlson, Eric P. Tamm, Wei Qiao, Robert A. Wolff, James L. Abbruzzese, and David R. Fogelman. “The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.” Cancer Chemother Pharmacol 69, no. 2 (February 2012): 425–30. https://doi.org/10.1007/s00280-011-1705-x.
       Full Text  Link to Item
    • Hammond-Thelin, Lisa A., Melanie B. Thomas, Michiko Iwasaki, James L. Abbruzzese, Yvonne Lassere, Christina A. Meyers, Paulo Hoff, et al. “Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.” Invest New Drugs 30, no. 1 (February 2012): 316–26. https://doi.org/10.1007/s10637-010-9535-y.
       Full Text  Link to Item
    • Estrella, Jeannelyn S., Asif Rashid, Jason B. Fleming, Matthew H. Katz, Jeffrey E. Lee, Robert A. Wolf, Gauri R. Varadhachary, et al. “Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.” Cancer 118, no. 1 (January 1, 2012): 268–77. https://doi.org/10.1002/cncr.26243.
       Full Text  Link to Item
    • Kaseb, Ahmed O., E. Garrett-Mayer, J. S. Morris, L. Xiao, E. Lin, G. Onicescu, M. M. Hassan, et al. “Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.” Oncology 82, no. 2 (2012): 67–74. https://doi.org/10.1159/000335963.
       Full Text  Link to Item
    • Katz, Matthew H. G., Huamin Wang, Aparna Balachandran, Priya Bhosale, Christopher H. Crane, Xuemei Wang, Peter W. T. Pisters, et al. “Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.” J Gastrointest Surg 16, no. 1 (January 2012): 68–78. https://doi.org/10.1007/s11605-011-1748-7.
       Full Text  Link to Item
    • Zhao, Qing, Asif Rashid, Yun Gong, Matthew H. Katz, Jeffrey E. Lee, Robert Wolf, Aparna Balachandran, et al. “Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.” Ann Diagn Pathol 16, no. 1 (January 2012): 29–37. https://doi.org/10.1016/j.anndiagpath.2011.08.005.
       Full Text  Link to Item
    • Fogelman, David, Mehrdad Jafari, Gauri R. Varadhachary, Henry Xiong, Susie Bullock, Harold Ozer, E. Lin, et al. “Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.” Cancer Chemother Pharmacol 68, no. 6 (December 2011): 1431–38. https://doi.org/10.1007/s00280-011-1601-4.
       Full Text  Link to Item
    • Chang, David Z., Ying Ma, Baoan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yong-jun Liu, Craig D. Logsdon, and Patrick Hwu. “Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.” Clin Cancer Res 17, no. 22 (November 15, 2011): 7015–23. https://doi.org/10.1158/1078-0432.CCR-11-0607.
       Full Text  Link to Item
    • Kaseb, Ahmed O., Jeffrey S. Morris, Manal M. Hassan, Adnan M. Siddiqui, E. Lin, Lianchun Xiao, Eddie K. Abdalla, et al. “Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.” J Clin Oncol 29, no. 29 (October 10, 2011): 3892–99. https://doi.org/10.1200/JCO.2011.36.0636.
       Full Text  Link to Item
    • Carbone, Carmine, Tania Moccia, Cihui Zhu, Genni Paradiso, Alfredo Budillon, Paul J. Chiao, James L. Abbruzzese, and Davide Melisi. “Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.” Clin Cancer Res 17, no. 17 (September 1, 2011): 5822–32. https://doi.org/10.1158/1078-0432.CCR-11-1185.
       Full Text  Link to Item
    • Melisi, Davide, Qianghua Xia, Genni Paradiso, Jianhua Ling, Tania Moccia, Carmine Carbone, Alfredo Budillon, James L. Abbruzzese, and Paul J. Chiao. “Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.” J Natl Cancer Inst 103, no. 15 (August 3, 2011): 1190–1204. https://doi.org/10.1093/jnci/djr243.
       Full Text  Link to Item
    • Abbruzzese, James L. “Introducing CCR perspectives in drug approval.” Clin Cancer Res 17, no. 15 (August 1, 2011): 4929. https://doi.org/10.1158/1078-0432.CCR-11-1479.
       Full Text  Link to Item
    • Crane, Christopher H., Gauri R. Varadhachary, John S. Yordy, Gregg A. Staerkel, Milind M. Javle, Howard Safran, Waqar Haque, et al. “Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.” J Clin Oncol 29, no. 22 (August 1, 2011): 3037–43. https://doi.org/10.1200/JCO.2010.33.8038.
       Full Text  Link to Item
    • El-Rayes, Bassel Fuad, Philip A. Philip, Fazlul H. Sarkar, Anthony F. Shields, Ann Marie Ferris, Kenneth Hess, Ahmad O. Kaseb, et al. “A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.” Invest New Drugs 29, no. 4 (August 2011): 694–99. https://doi.org/10.1007/s10637-010-9386-6.
       Full Text  Link to Item
    • Tanaka, Motofumi, Ping Chang, Yanan Li, Donghui Li, Michael Overman, Dipen M. Maru, Salil Sethi, et al. “Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.” Clin Cancer Res 17, no. 13 (July 1, 2011): 4531–40. https://doi.org/10.1158/1078-0432.CCR-10-0763.
       Full Text  Link to Item
    • Varadhachary, Gauri R., Yael Spector, James L. Abbruzzese, Shai Rosenwald, Huamin Wang, Ranit Aharonov, Heather R. Carlson, et al. “Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4063–70. https://doi.org/10.1158/1078-0432.CCR-10-2599.
       Full Text  Link to Item
    • Kaseb, Ahmed O., Manal M. Hassan, E. Lin, Lianchun Xiao, Vikas Kumar, Priyanka Pathak, Richard Lozano, Asif Rashid, James L. Abbruzzese, and Jeffrey S. Morris. “V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.” Cancer 117, no. 11 (June 1, 2011): 2478–88. https://doi.org/10.1002/cncr.25791.
       Full Text  Link to Item
    • Dong, Xiaoqun, Yanan Li, Ping Chang, Hongwei Tang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “Glucose metabolism gene variants modulate the risk of pancreatic cancer.” Cancer Prev Res (Phila) 4, no. 5 (May 2011): 758–66. https://doi.org/10.1158/1940-6207.CAPR-10-0247.
       Full Text  Link to Item
    • Tang, Hongwei, Xiaoqun Dong, Manal Hassan, James L. Abbruzzese, and Donghui Li. “Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer.” Cancer Epidemiol Biomarkers Prev 20, no. 5 (May 2011): 779–92. https://doi.org/10.1158/1055-9965.EPI-10-0845.
       Full Text  Link to Item
    • Bernatchez, Chantale, Kuichin Zhu, Yufeng Li, Helen Andersson, Constantin Ionnides, Marcelo Fernandez-Vina, Pedro Cano, et al. “Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals.” Vaccine 29, no. 16 (April 5, 2011): 3021–30. https://doi.org/10.1016/j.vaccine.2011.01.115.
       Full Text  Link to Item
    • Fogelman, David R., Robert A. Wolff, Scott Kopetz, Milind Javle, Charles Bradley, Isabel Mok, Fernando Cabanillas, and James L. Abbruzzese. “Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.” Anticancer Res 31, no. 4 (April 2011): 1417–20.
       Link to Item
    • Ramanathan, Ramesh K., James Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose M. Guillen, Amanda F. Baker, Linda A. Pestano, Sylvan Green, and Daniel D. Von Hoff. “A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.” Cancer Chemother Pharmacol 67, no. 3 (March 2011): 503–9. https://doi.org/10.1007/s00280-010-1343-8.
       Full Text  Link to Item
    • Song, Xianzhou, Hua Wang, Craig D. Logsdon, Asif Rashid, Jason B. Fleming, James L. Abbruzzese, Henry F. Gomez, Douglas B. Evans, and Huamin Wang. “Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.” Cancer 117, no. 4 (February 15, 2011): 734–43. https://doi.org/10.1002/cncr.25483.
       Full Text  Link to Item
    • Tanaka, Motofumi, Taro Okazaki, Hideo Suzuki, James L. Abbruzzese, and Donghui Li. “Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.” Cancer 117, no. 4 (February 15, 2011): 744–51. https://doi.org/10.1002/cncr.25510.
       Full Text  Link to Item
    • Dong, Xiaoqun, Hongwei Tang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer.” Cancer 117, no. 3 (February 1, 2011): 480–91. https://doi.org/10.1002/cncr.25612.
       Full Text  Link to Item
    • Basha, R., C. T. Baker, U. T. Sankpal, S. Ahmad, S. Safe, J. L. Abbruzzese, and M. Abdelrahim. “Therapeutic applications of NSAIDS in cancer: Special emphasis on tolfenamic acid.” Frontiers in Bioscience  Scholar 3 S, no. 2 (2011): 797–805.
    • Basha, Riyaz, Cheryl H. Baker, Umesh T. Sankpal, Sarfraz Ahmad, Stephen Safe, James L. Abbruzzese, and Maen Abdelrahim. “Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.” Front Biosci (Schol Ed) 3, no. 2 (January 1, 2011): 797–805. https://doi.org/10.2741/s188.
       Full Text  Link to Item
    • Dong, Xiaoqun, Yanan Li, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.” Oncologist 16, no. 1 (2011): 61–70. https://doi.org/10.1634/theoncologist.2010-0127.
       Full Text  Link to Item
    • Kaseb, Ahmed O., James L. Abbruzzese, Jean-Nicolas Vauthey, Thomas A. Aloia, Eddie K. Abdalla, Manal M. Hassan, E. Lin, et al. “I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.” Oncology 80, no. 5–6 (2011): 373–81. https://doi.org/10.1159/000329040.
       Full Text  Link to Item
    • Kim, Michael P., Jason B. Fleming, Huamin Wang, James L. Abbruzzese, Woonyoung Choi, Scott Kopetz, David J. McConkey, Douglas B. Evans, and Gary E. Gallick. “ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.” Plos One 6, no. 6 (2011): e20636. https://doi.org/10.1371/journal.pone.0020636.
       Full Text  Link to Item
    • Tanaka, Motofumi, Milind Javle, Xiaoqun Dong, Cathy Eng, James L. Abbruzzese, and Donghui Li. “Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.” Cancer 116, no. 22 (November 15, 2010): 5325–35. https://doi.org/10.1002/cncr.25282.
       Full Text  Link to Item
    • Logsdon, Craig D., and James L. Abbruzzese. “Chemoprevention of pancreatic cancer: ready for the clinic?” Cancer Prev Res (Phila) 3, no. 11 (November 2010): 1375–78. https://doi.org/10.1158/1940-6207.CAPR-10-0216.
       Full Text  Link to Item
    • Kidd, Shannon, Lisa Caldwell, Martin Dietrich, Ismael Samudio, Erika L. Spaeth, Keri Watson, Yuexi Shi, et al. “Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.” Cytotherapy 12, no. 5 (September 2010): 615–25. https://doi.org/10.3109/14653241003631815.
       Full Text  Link to Item
    • Li, Donghui, and James L. Abbruzzese. “New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.” Clin Cancer Res 16, no. 17 (September 1, 2010): 4313–18. https://doi.org/10.1158/1078-0432.CCR-09-1942.
       Full Text  Link to Item
    • Dong, Xiaoqun, Milind Javle, Kenneth R. Hess, Rachna Shroff, James L. Abbruzzese, and Donghui Li. “Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.” Gastroenterology 139, no. 2 (August 2010): 464-473.e3. https://doi.org/10.1053/j.gastro.2010.04.042.
       Full Text  Link to Item
    • Philip, Philip A., Jacqueline Benedetti, Christopher L. Corless, Ralph Wong, Eileen M. O’Reilly, Patrick J. Flynn, Kendrith M. Rowland, et al. “Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.” J Clin Oncol 28, no. 22 (August 1, 2010): 3605–10. https://doi.org/10.1200/JCO.2009.25.7550.
       Full Text  Link to Item
    • Peng, Lan, John Liang, Hua Wang, Xianzhou Song, Asif Rashid, Henry F. Gomez, Lynda J. Corley, et al. “High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma.” Clin Cancer Res 16, no. 14 (July 15, 2010): 3734–42. https://doi.org/10.1158/1078-0432.CCR-09-3411.
       Full Text  Link to Item
    • Javle, Milind M., Rachna T. Shroff, Henry Xiong, Gauri A. Varadhachary, David Fogelman, Shrikanth A. Reddy, Darren Davis, Yujian Zhang, Robert A. Wolff, and James L. Abbruzzese. “Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.” Bmc Cancer 10 (July 14, 2010): 368. https://doi.org/10.1186/1471-2407-10-368.
       Full Text  Link to Item
    • Katz, Matthew H. G., Gauri R. Varadhachary, Jason B. Fleming, Robert A. Wolff, Jeffrey E. Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, et al. “Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.” Ann Surg Oncol 17, no. 7 (July 2010): 1794–1801. https://doi.org/10.1245/s10434-010-0943-1.
       Full Text  Link to Item
    • Overman, Michael J., Scott Kopetz, E. Lin, James L. Abbruzzese, and Robert A. Wolff. “Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.” Acta Oncol 49, no. 4 (May 2010): 474–79. https://doi.org/10.3109/02841860903490051.
       Full Text  Link to Item
    • Hassan, Manal M., Steven A. Curley, Donghui Li, Ahmed Kaseb, Marta Davila, Eddie K. Abdalla, Milind Javle, et al. “Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.” Cancer 116, no. 8 (April 15, 2010): 1938–46. https://doi.org/10.1002/cncr.24982.
       Full Text  Link to Item
    • Blanke, Charles D., Kari Chansky, Kathy L. Christman, Scott A. Hundahl, Brian F. Issell, Peter J. Van Veldhuizen, G Thomas Budd, James L. Abbruzzese, and John S. Macdonald. “S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.” Am J Clin Oncol 33, no. 2 (April 2010): 117–20. https://doi.org/10.1097/COC.0b013e318199fb84.
       Full Text  Link to Item
    • Overman, Michael J., Syed M. Kazmi, Jagriti Jhamb, E. Lin, James C. Yao, James L. Abbruzzese, Linus Ho, Jaffer Ajani, and Alexandria Phan. “Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.” Cancer 116, no. 6 (March 15, 2010): 1446–53. https://doi.org/10.1002/cncr.24925.
       Full Text  Link to Item
    • Abbruzzese, James L., Alexander M. M. Eggermont, and Eric H. Rubin. “Introducing new strategies in..” Clin Cancer Res 16, no. 5 (March 1, 2010): 1347. https://doi.org/10.1158/1078-0432.CCR-10-0236.
       Full Text  Link to Item
    • Kopetz, Scott, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, Rosie Adinin, et al. “Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.” J Clin Oncol 28, no. 3 (January 20, 2010): 453–59. https://doi.org/10.1200/JCO.2009.24.8252.
       Full Text  Link to Item
    • Pino, M. S., M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey. “Correction: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines (Cancer Research (2006) 66, 7, (3802-3812)).” Cancer Research 70, no. 2 (January 15, 2010): 852–53. https://doi.org/10.1158/0008-5472.CAN-09-4221.
       Full Text
    • Overman, M. J., J. Pozadzides, S. Kopetz, S. Wen, J. L. Abbruzzese, R. A. Wolff, and H. Wang. “Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.” Br J Cancer 102, no. 1 (January 5, 2010): 144–50. https://doi.org/10.1038/sj.bjc.6605449.
       Full Text  Link to Item
    • Okazaki, Taro, Milind Javle, Motofumi Tanaka, James L. Abbruzzese, and Donghui Li. “Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.” Clin Cancer Res 16, no. 1 (January 1, 2010): 320–29. https://doi.org/10.1158/1078-0432.CCR-09-1555.
       Full Text  Link to Item
    • Kopetz, S., and J. L. Abbruzzese. “Barriers to integrating gene profiling for stage II colon cancer.” Clinical Cancer Research 15, no. 24 (December 15, 2009): 7451–52. https://doi.org/10.1158/1078-0432.CCR-09-2523.
       Full Text
    • Reyes-Gibby, Cielito C., Sanjay Shete, Sriram Yennurajalingam, Marsha Frazier, Eduardo Bruera, Razelle Kurzrock, Christopher H. Crane, James Abbruzzese, Douglas Evans, and Margaret R. Spitz. “Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.” J Pain Symptom Manage 38, no. 6 (December 2009): 894–902. https://doi.org/10.1016/j.jpainsymman.2009.04.019.
       Full Text  Link to Item
    • Hassan, M. M., and J. L. Abbruzzese. “Reply.” Hepatology 50, no. 3 (November 27, 2009): 994. https://doi.org/10.1002/hep.23172.
       Full Text
    • Philip, Philip A., Margaret Mooney, Deborah Jaffe, Gail Eckhardt, Malcolm Moore, Neal Meropol, Leisha Emens, et al. “Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.” J Clin Oncol 27, no. 33 (November 20, 2009): 5660–69. https://doi.org/10.1200/JCO.2009.21.9022.
       Full Text  Link to Item
    • Melisi, Davide, Valeria Ossovskaya, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese, and Paul J. Chiao. “Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.” Clin Cancer Res 15, no. 20 (October 15, 2009): 6367–77. https://doi.org/10.1158/1078-0432.CCR-09-0910.
       Full Text  Link to Item
    • Whitehead, Robert P., Cathryn Rankin, Paulo M. G. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert A. Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese, and Charles D. Blanke. “Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).” Invest New Drugs 27, no. 5 (October 2009): 469–75. https://doi.org/10.1007/s10637-008-9190-8.
       Full Text  Link to Item
    • Li, Donghui, Sai-Ching J. Yeung, Manal M. Hassan, Marina Konopleva, and James L. Abbruzzese. “Antidiabetic therapies affect risk of pancreatic cancer.” Gastroenterology 137, no. 2 (August 2009): 482–88. https://doi.org/10.1053/j.gastro.2009.04.013.
       Full Text  Link to Item
    • Arumugam, Thiruvengadam, Vijaya Ramachandran, Keith F. Fournier, Huamin Wang, Lauren Marquis, James L. Abbruzzese, Gary E. Gallick, Craig D. Logsdon, David J. McConkey, and Woonyoung Choi. “Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.” Cancer Res 69, no. 14 (July 15, 2009): 5820–28. https://doi.org/10.1158/0008-5472.CAN-08-2819.
       Full Text  Link to Item
    • Li, Donghui, Jeffrey S. Morris, Jun Liu, Manal M. Hassan, R Sue Day, Melissa L. Bondy, and James L. Abbruzzese. “Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.” Jama 301, no. 24 (June 24, 2009): 2553–62. https://doi.org/10.1001/jama.2009.886.
       Full Text  Link to Item
    • Overman, Michael J., Gauri R. Varadhachary, Scott Kopetz, Rosni Adinin, E. Lin, Jeffrey S. Morris, Cathy Eng, James L. Abbruzzese, and Robert A. Wolff. “Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.” J Clin Oncol 27, no. 16 (June 1, 2009): 2598–2603. https://doi.org/10.1200/JCO.2008.19.7145.
       Full Text  Link to Item
    • Kopetz, Scott, Donald P. Lesslie, Nikolas A. Dallas, Serk I. Park, Marjorie Johnson, Nila U. Parikh, Michael P. Kim, et al. “Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.” Cancer Res 69, no. 9 (May 1, 2009): 3842–49. https://doi.org/10.1158/0008-5472.CAN-08-2246.
       Full Text  Link to Item
    • Hassan, Manal M., Ahmed Kaseb, Donghui Li, Yehuda Z. Patt, Jean-Nicolas Vauthey, Melanie B. Thomas, Steven A. Curley, et al. “Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.” Hepatology 49, no. 5 (May 2009): 1563–70. https://doi.org/10.1002/hep.22793.
       Full Text  Link to Item
    • Shin, Sonyo, Takayuki Asano, Yixin Yao, Ronghua Zhang, Francois-Xavier Claret, Murray Korc, Kanaga Sabapathy, David G. Menter, James L. Abbruzzese, and Shrikanth A. G. Reddy. “Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism.” Mol Cancer Res 7, no. 5 (May 2009): 745–54. https://doi.org/10.1158/1541-7786.MCR-08-0462.
       Full Text  Link to Item
    • Dong, Xiaoqun, Li Jiao, Yanan Li, Douglas B. Evans, Huamin Wang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.” J Clin Oncol 27, no. 10 (April 1, 2009): 1592–99. https://doi.org/10.1200/JCO.2008.20.1111.
       Full Text  Link to Item
    • Kopetz, Scott, and James L. Abbruzzese. “Hidden biases in an observational study of bevacizumab beyond progression.” J Clin Oncol 27, no. 10 (April 1, 2009): 1732–33. https://doi.org/10.1200/JCO.2009.21.2084.
       Full Text  Link to Item
    • Wang, Zhiwei, Yiwei Li, Dejuan Kong, Sanjeev Banerjee, Aamir Ahmad, Asfar Sohail Azmi, Shadan Ali, James L. Abbruzzese, Gary E. Gallick, and Fazlul H. Sarkar. “Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.” Cancer Res 69, no. 6 (March 15, 2009): 2400–2407. https://doi.org/10.1158/0008-5472.CAN-08-4312.
       Full Text  Link to Item
    • Konduri, Santhi, Jimmie Colon, Cheryl H. Baker, Stephen Safe, James L. Abbruzzese, Ala Abudayyeh, Md Riyaz Basha, and Maen Abdelrahim. “Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.” Mol Cancer Ther 8, no. 3 (March 2009): 533–42. https://doi.org/10.1158/1535-7163.MCT-08-0405.
       Full Text  Link to Item
    • Thomas, Melanie B., Jeffrey S. Morris, Romil Chadha, Michiko Iwasaki, Harmeet Kaur, E. Lin, Ahmed Kaseb, Katrina Glover, Marta Davila, and James Abbruzzese. “Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.” J Clin Oncol 27, no. 6 (February 20, 2009): 843–50. https://doi.org/10.1200/JCO.2008.18.3301.
       Full Text  Link to Item
    • Sui, X., S. Shin, R. Zhang, P. F. Firozi, L. Yang, J. L. Abbruzzese, and S. A. G. Reddy. “Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.” Oncogene 28, no. 5 (February 5, 2009): 709–20. https://doi.org/10.1038/onc.2008.423.
       Full Text  Link to Item
    • Hassan, M. M., D. Li, and J. L. Abbruzzese. “In reply.” Journal of Clinical Oncology 27, no. 4 (February 1, 2009): 648–49. https://doi.org/10.1200/JCO.2008.20.8587.
       Full Text
    • Chen, Jinyun, Donghui Li, Ann M. Killary, Subrata Sen, Christopher I. Amos, Douglas B. Evans, James L. Abbruzzese, and Marsha L. Frazier. “Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.” Ann Surg Oncol 16, no. 2 (February 2009): 431–39. https://doi.org/10.1245/s10434-008-0220-8.
       Full Text  Link to Item
    • Hassan, Manal M., Margret R. Spitz, Melanie B. Thomas, Steven A. Curley, Yehuda Z. Patt, Jean-Nicolas Vauthey, Katrina Y. Glover, et al. “The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.” J Hepatol 50, no. 2 (February 2009): 334–41. https://doi.org/10.1016/j.jhep.2008.08.016.
       Full Text  Link to Item
    • Wang, Hua, Xianzhou Song, Craig Logsdon, Guisheng Zhou, Douglas B. Evans, James L. Abbruzzese, Stanley R. Hamilton, Tse-Hua Tan, and Huamin Wang. “Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.” Cancer Res 69, no. 3 (February 1, 2009): 1063–70. https://doi.org/10.1158/0008-5472.CAN-08-1751.
       Full Text  Link to Item
    • Li, Donghui, Hideo Suzuki, Bingrong Liu, Jeffrey Morris, Jun Liu, Taro Okazaki, Yanan Li, Ping Chang, and James L. Abbruzzese. “DNA repair gene polymorphisms and risk of pancreatic cancer.” Clin Cancer Res 15, no. 2 (January 15, 2009): 740–46. https://doi.org/10.1158/1078-0432.CCR-08-1607.
       Full Text  Link to Item
    • Kim, Michael P., Douglas B. Evans, Huamin Wang, James L. Abbruzzese, Jason B. Fleming, and Gary E. Gallick. “Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.” Nat Protoc 4, no. 11 (2009): 1670–80. https://doi.org/10.1038/nprot.2009.171.
       Full Text  Link to Item
    • Ng, Chaan S., Yoshihisa Kodama, Nizar A. Mullani, Bruce J. Barron, Wei Wei, Roy S. Herbst, James L. Abbruzzese, and Chusilp Charnsangavej. “Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.” J Comput Assist Tomogr 33, no. 3 (2009): 460–65. https://doi.org/10.1097/RCT.0b013e318182d2e0.
       Full Text  Link to Item
    • Chen, Jinyun, Ann M. Killary, Subrata Sen, Christopher I. Amos, Douglas B. Evans, James L. Abbruzzese, and Marsha L. Frazier. “Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer.” Cancer Lett 272, no. 1 (December 8, 2008): 32–39. https://doi.org/10.1016/j.canlet.2008.06.022.
       Full Text  Link to Item
    • Higginbotham, Kimberly B., Richard Lozano, Thomas Brown, Yehuda Z. Patt, Takashi Arima, James L. Abbruzzese, and Melanie B. Thomas. “A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.” J Cancer Res Clin Oncol 134, no. 12 (December 2008): 1325–35. https://doi.org/10.1007/s00432-008-0406-2.
       Full Text  Link to Item
    • Suzuki, Hideo, Yanan Li, Xiaoqun Dong, Manal M. Hassan, James L. Abbruzzese, and Donghui Li. “Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.” Cancer Epidemiol Biomarkers Prev 17, no. 12 (December 2008): 3467–73. https://doi.org/10.1158/1055-9965.EPI-08-0514.
       Full Text  Link to Item
    • Varadhachary, Gauri R., and James L. Abbruzzese. “Novel approaches to 'borderline resectable' pancreatic tumors.” Oncology (Williston Park) 22, no. 13 (November 30, 2008): 1529–30.
       Link to Item
    • Liang, John J., Hua Wang, Asif Rashid, Tse-Hua Tan, Rosa F. Hwang, Stanley R. Hamilton, James L. Abbruzzese, Douglas B. Evans, and Huamin Wang. “Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7043–49. https://doi.org/10.1158/1078-0432.CCR-08-0381.
       Full Text  Link to Item
    • Hassan, Manal M., Margaret R. Spitz, Melanie B. Thomas, Adel S. El-Deeb, Katrina Y. Glover, Nga T. Nguyen, Wenyaw Chan, et al. “Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study.” Int J Cancer 123, no. 8 (October 15, 2008): 1883–91. https://doi.org/10.1002/ijc.23730.
       Full Text  Link to Item
    • Overman, Michael J., Scott Kopetz, Sijin Wen, Paulo M. Hoff, David Fogelman, Jeffrey Morris, James L. Abbruzzese, Jaffer A. Ajani, and Robert A. Wolff. “Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.” Cancer 113, no. 8 (October 15, 2008): 2038–45. https://doi.org/10.1002/cncr.23822.
       Full Text  Link to Item
    • Xiong, Henry Q., Gauri R. Varadhachary, Joan C. Blais, Kenneth R. Hess, James L. Abbruzzese, and Robert A. Wolff. “Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.” Cancer 113, no. 8 (October 15, 2008): 2046–52. https://doi.org/10.1002/cncr.23810.
       Full Text  Link to Item
    • Hassan, Manal M., Donghui Li, Adel S. El-Deeb, Robert A. Wolff, Melissa L. Bondy, Marta Davila, and James L. Abbruzzese. “Association between hepatitis B virus and pancreatic cancer.” J Clin Oncol 26, no. 28 (October 1, 2008): 4557–62. https://doi.org/10.1200/JCO.2008.17.3526.
       Full Text  Link to Item
    • Overman, Michael J., Gauri Varadhachary, Scott Kopetz, Melanie B. Thomas, Masakazu Fukushima, Keizo Kuwata, Akira Mita, et al. “Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.” Invest New Drugs 26, no. 5 (October 2008): 445–54. https://doi.org/10.1007/s10637-008-9142-3.
       Full Text  Link to Item
    • Overman, Michael J., Scott Kopetz, Gauri Varadhachary, Masakazu Fukushima, Keizo Kuwata, Akira Mita, Robert A. Wolff, Paulo Hoff, Henry Xiong, and James L. Abbruzzese. “Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.” Cancer Invest 26, no. 8 (October 2008): 794–99. https://doi.org/10.1080/07357900802087242.
       Full Text  Link to Item
    • Varadhachary, Gauri R., Dmitri Talantov, Martin N. Raber, Christina Meng, Kenneth R. Hess, Tim Jatkoe, Renato Lenzi, et al. “Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.” J Clin Oncol 26, no. 27 (September 20, 2008): 4442–48. https://doi.org/10.1200/JCO.2007.14.4378.
       Full Text  Link to Item
    • Hoff, P. M., S. Kopetz, M. B. Thomas, A. Langleben, D. Rinaldi, L. Anthony, R. A. Wolff, Y. Lassere, and J. L. Abbruzzese. “A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.” Br J Cancer 99, no. 5 (September 2, 2008): 722–26. https://doi.org/10.1038/sj.bjc.6604541.
       Full Text  Link to Item
    • Reddy, Nischita K., Avi B. Markowitz, James L. Abbruzzese, and Manoop S. Bhutani. “Knowledge of indications and utilization of EUS: a survey of oncologists in the United States.” J Clin Gastroenterol 42, no. 8 (September 2008): 892–96. https://doi.org/10.1097/MCG.0b013e3180cab11a.
       Full Text  Link to Item
    • Wei, Yongkun, Weiya Xia, Zhihong Zhang, Jinsong Liu, Huamin Wang, Nazmi V. Adsay, Constance Albarracin, et al. “Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.” Mol Carcinog 47, no. 9 (September 2008): 701–6. https://doi.org/10.1002/mc.20413.
       Full Text  Link to Item
    • Wang, Zhiwei, Sita Desmoulin, Sanjeev Banerjee, Dejuan Kong, Yiwei Li, Rohan L. Deraniyagala, James Abbruzzese, and Fazlul H. Sarkar. “Synergistic effects of multiple natural products in pancreatic cancer cells.” Life Sci 83, no. 7–8 (August 15, 2008): 293–300. https://doi.org/10.1016/j.lfs.2008.06.017.
       Full Text  Link to Item
    • Evans, Douglas B., Gauri R. Varadhachary, Christopher H. Crane, Charlotte C. Sun, Jeffrey E. Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, et al. “Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.” J Clin Oncol 26, no. 21 (July 20, 2008): 3496–3502. https://doi.org/10.1200/JCO.2007.15.8634.
       Full Text  Link to Item
    • Varadhachary, Gauri R., Robert A. Wolff, Christopher H. Crane, Charlotte C. Sun, Jeffrey E. Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, et al. “Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.” J Clin Oncol 26, no. 21 (July 20, 2008): 3487–95. https://doi.org/10.1200/JCO.2007.15.8642.
       Full Text  Link to Item
    • Dhillon, Navneet, Bharat B. Aggarwal, Robert A. Newman, Robert A. Wolff, Ajaikumar B. Kunnumakkara, James L. Abbruzzese, Chaan S. Ng, Vladimir Badmaev, and Razelle Kurzrock. “Phase II trial of curcumin in patients with advanced pancreatic cancer.” Clin Cancer Res 14, no. 14 (July 15, 2008): 4491–99. https://doi.org/10.1158/1078-0432.CCR-08-0024.
       Full Text  Link to Item
    • Suzuki, Hideo, Jeffrey S. Morris, Yanan Li, Mark A. Doll, David W. Hein, Jun Liu, Li Jiao, et al. “Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.” Carcinogenesis 29, no. 6 (June 2008): 1184–91. https://doi.org/10.1093/carcin/bgn085.
       Full Text  Link to Item
    • Varadhachary, Gauri R., Martin N. Raber, Aurelio Matamoros, and James L. Abbruzzese. “Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.” Lancet Oncol 9, no. 6 (June 2008): 596–99. https://doi.org/10.1016/S1470-2045(08)70151-7.
       Full Text  Link to Item
    • Hwang, Rosa F., Huamin Wang, Axbal Lara, Henry Gomez, Tracy Chang, Nicole Sieffert, Younghee Moon, et al. “Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.” Ann Surg Oncol 15, no. 5 (May 2008): 1356–66. https://doi.org/10.1245/s10434-008-9833-1.
       Full Text  Link to Item
    • Kopetz, Scott, Michael Overman, David Z. Chang, Katrina Y. Glover, Imad Shureiqi, Robert A. Wolff, James L. Abbruzzese, and Cathy Eng. “Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.” J Clin Oncol 26, no. 12 (April 20, 2008): 2000–2005. https://doi.org/10.1200/JCO.2007.13.2407.
       Full Text  Link to Item
    • Melisi, Davide, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese, and Paul J. Chiao. “LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.” Mol Cancer Ther 7, no. 4 (April 2008): 829–40. https://doi.org/10.1158/1535-7163.MCT-07-0337.
       Full Text  Link to Item
    • Mullani, Nizar A., Roy S. Herbst, Roger G. O’Neil, K Lance Gould, Bruce J. Barron, and James L. Abbruzzese. “Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.” J Nucl Med 49, no. 4 (April 2008): 517–23. https://doi.org/10.2967/jnumed.107.048504.
       Full Text  Link to Item
    • Okazaki, Taro, Li Jiao, Ping Chang, Douglas B. Evans, James L. Abbruzzese, and Donghui Li. “Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.” Clin Cancer Res 14, no. 7 (April 1, 2008): 2042–48. https://doi.org/10.1158/1078-0432.CCR-07-1520.
       Full Text  Link to Item
    • Verma, Amit, Sushovan Guha, Huamin Wang, Jansina Y. Fok, Dimpy Koul, James Abbruzzese, and Kapil Mehta. “Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.” Clin Cancer Res 14, no. 7 (April 1, 2008): 1997–2005. https://doi.org/10.1158/1078-0432.CCR-07-1533.
       Full Text  Link to Item
    • Yao, James C., Alexandria Phan, Paulo M. Hoff, Helen X. Chen, Chusilp Charnsangavej, Sai-Ching J. Yeung, Kenneth Hess, Chaan Ng, James L. Abbruzzese, and Jaffer A. Ajani. “Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.” J Clin Oncol 26, no. 8 (March 10, 2008): 1316–23. https://doi.org/10.1200/JCO.2007.13.6374.
       Full Text  Link to Item
    • Abbruzzese, James L. “Adjuvant therapy for surgically resected pancreatic adenocarcinoma.” Jama 299, no. 9 (March 5, 2008): 1066–67. https://doi.org/10.1001/jama.299.9.1066.
       Full Text  Link to Item
    • Jiao, Li, Manal M. Hassan, Melissa L. Bondy, Robert A. Wolff, Douglas B. Evans, James L. Abbruzzese, and Donghui Li. “XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer.” Am J Gastroenterol 103, no. 2 (February 2008): 360–67. https://doi.org/10.1111/j.1572-0241.2007.01615.x.
       Full Text  Link to Item
    • Thomas, Melanie B., Marta Davila, and James L. Abbruzzese. “Stemming the tide of hepatitis B virus related hepatocellular carcinoma?” J Clin Oncol 26, no. 2 (January 10, 2008): 172–74. https://doi.org/10.1200/JCO.2007.14.4337.
       Full Text  Link to Item
    • Politano, S., M. Overman, P. Pathak, R. Chadha, K. Glover, D. Z. Chang, R. A. Wolff, et al. “Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness.” Clinical Colorectal Cancer 7, no. 1 (January 1, 2008): 55–59. https://doi.org/10.3816/CCC.2008.n.008.
       Full Text
    • Hassan, Manal M., Melissa L. Bondy, Robert A. Wolff, James L. Abbruzzese, Jean-Nicolas Vauthey, Peter W. Pisters, Douglas B. Evans, et al. “Risk factors for pancreatic cancer: case-control study.” Am J Gastroenterol 102, no. 12 (December 2007): 2696–2707. https://doi.org/10.1111/j.1572-0241.2007.01510.x.
       Full Text  Link to Item
    • Wang, Zhiwei, Dejuan Kong, Sanjeev Banerjee, Yiwei Li, N Volkan Adsay, James Abbruzzese, and Fazlul H. Sarkar. “Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.” Cancer Res 67, no. 23 (December 1, 2007): 11377–85. https://doi.org/10.1158/0008-5472.CAN-07-2803.
       Full Text  Link to Item
    • Zhu, Kuichun, Hong Qin, Soung-Chul Cha, Sattva S. Neelapu, Willem Overwijk, Gregory A. Lizee, James L. Abbruzzese, et al. “Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.” Vaccine 25, no. 46 (November 14, 2007): 7955–61. https://doi.org/10.1016/j.vaccine.2007.08.050.
       Full Text  Link to Item
    • Fogelman, D. R., and J. L. Abbruzzese. “'Unresectable' pancreatic cancer: Conceptual challenges.” Oncology 21, no. 13 (November 1, 2007): 1571–72.
    • Jiao, Li, Mark A. Doll, David W. Hein, Melissa L. Bondy, Manal M. Hassan, James E. Hixson, James L. Abbruzzese, and Donghui Li. “Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.” Cancer Epidemiol Biomarkers Prev 16, no. 11 (November 2007): 2379–86. https://doi.org/10.1158/1055-9965.EPI-06-0992.
       Full Text  Link to Item
    • Lo, Hui-Wen, Sheng-Chieh Hsu, Weiya Xia, Xinyu Cao, Jin-Yuan Shih, Yongkun Wei, James L. Abbruzzese, Gabriel N. Hortobagyi, and Mien-Chie Hung. “Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.” Cancer Res 67, no. 19 (October 1, 2007): 9066–76. https://doi.org/10.1158/0008-5472.CAN-07-0575.
       Full Text  Link to Item
    • Reyes-Gibby, Cielito C., Wenyaw Chan, James L. Abbruzzese, Henry Q. Xiong, Linus Ho, Douglas B. Evans, Gauri Varadhachary, Samrat Bhat, Robert A. Wolff, and Christopher Crane. “Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.” J Pain Symptom Manage 34, no. 3 (September 2007): 244–52. https://doi.org/10.1016/j.jpainsymman.2006.11.007.
       Full Text  Link to Item
    • Thomas, Melanie B., Romil Chadha, Katrina Glover, Xuemei Wang, Jeffrey Morris, Thomas Brown, Asif Rashid, Janet Dancey, and James L. Abbruzzese. “Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.” Cancer 110, no. 5 (September 1, 2007): 1059–67. https://doi.org/10.1002/cncr.22886.
       Full Text  Link to Item
    • Lo, An-Chi, Amr S. Soliman, Nabih El-Ghawalby, Mohamed Abdel-Wahab, Omar Fathy, Hussein M. Khaled, Sherif Omar, Stanley R. Hamilton, Joel K. Greenson, and James L. Abbruzzese. “Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk.” Pancreas 35, no. 2 (August 2007): 120–29. https://doi.org/10.1097/mpa.0b013e318053e7d3.
       Full Text  Link to Item
    • Soliman, Amr S., An-Chi Lo, Mousumi Banerjee, Nabih El-Ghawalby, Hussein M. Khaled, Sherif Bayoumi, Ibrahim A. Seifeldin, et al. “Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.” Carcinogenesis 28, no. 8 (August 2007): 1794–99. https://doi.org/10.1093/carcin/bgm138.
       Full Text  Link to Item
    • Gutierrez-Barrera, Angelica M., David G. Menter, James L. Abbruzzese, and Shrikanth A. G. Reddy. “Establishment of three-dimensional cultures of human pancreatic duct epithelial cells.” Biochem Biophys Res Commun 358, no. 3 (July 6, 2007): 698–703. https://doi.org/10.1016/j.bbrc.2007.04.166.
       Full Text  Link to Item
    • Cohen, Marlene Zichi, Jacquelyn Slomka, Rebecca D. Pentz, Anne L. Flamm, David Gold, Roy S. Herbst, and James L. Abbruzzese. “Phase I participants' views of quality of life and trial participation burdens.” Support Care Cancer 15, no. 7 (July 2007): 885–90. https://doi.org/10.1007/s00520-007-0216-0.
       Full Text  Link to Item
    • Krishnan, Sunil, Vishal Rana, Nora A. Janjan, Gauri R. Varadhachary, James L. Abbruzzese, Prajnan Das, Marc E. Delclos, et al. “Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.” Cancer 110, no. 1 (July 1, 2007): 47–55. https://doi.org/10.1002/cncr.22735.
       Full Text  Link to Item
    • Xie, Xiaoming, Weiya Xia, Zhongkui Li, Hsu-Ping Kuo, Yuanfang Liu, Zheng Li, Qingqing Ding, et al. “Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.” Cancer Cell 12, no. 1 (July 2007): 52–65. https://doi.org/10.1016/j.ccr.2007.05.009.
       Full Text  Link to Item
    • Hassan, Manal M., James L. Abbruzzese, Melissa L. Bondy, Robert A. Wolff, Jean-Nicolas Vauthey, Peter W. Pisters, Douglas B. Evans, et al. “Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study.” Cancer 109, no. 12 (June 15, 2007): 2547–56. https://doi.org/10.1002/cncr.22724.
       Full Text  Link to Item
    • Chen, Jinyun, Donghui Li, Chongjuan Wei, Subrata Sen, Ann M. Killary, Christopher I. Amos, Douglas B. Evans, James L. Abbruzzese, and Marsha L. Frazier. “Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians.” Clin Cancer Res 13, no. 10 (May 15, 2007): 3100–3104. https://doi.org/10.1158/1078-0432.CCR-06-2319.
       Full Text  Link to Item
    • Uwagawa, Tadashi, Zhongkui Li, Zhe Chang, Qianghua Xia, Bailu Peng, Guido M. Sclabas, Satoshi Ishiyama, et al. “Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.” Cancer 109, no. 10 (May 15, 2007): 2142–53. https://doi.org/10.1002/cncr.22658.
       Full Text  Link to Item
    • Cao, Dengfeng, Qian Zhang, Lee Shun-Fune Wu, Safia N. Salaria, Jordan W. Winter, Ralph H. Hruban, Michael S. Goggins, James L. Abbruzzese, Anirban Maitra, and Linus Ho. “Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.” Mod Pathol 20, no. 5 (May 2007): 570–78. https://doi.org/10.1038/modpathol.3800772.
       Full Text  Link to Item
    • Zhu, Kuichun, Gregory Lizee, Pedro Cano, Marcelo Fernando-Vina, Baoan Ji, James L. Abbruzzese, Patrick Hwu, Laszlo Radvanyi, and David Z. Chang. “HLA-A0201 positive pancreatic cell lines: new findings and discrepancies.” Cancer Immunol Immunother 56, no. 5 (May 2007): 719–24. https://doi.org/10.1007/s00262-006-0217-8.
       Full Text  Link to Item
    • Li, Donghui, Yanan Li, Li Jiao, David Z. Chang, Garth Beinart, Robert A. Wolff, Douglas B. Evans, Manal M. Hassan, and James L. Abbruzzese. “Effects of base excision repair gene polymorphisms on pancreatic cancer survival.” Int J Cancer 120, no. 8 (April 15, 2007): 1748–54. https://doi.org/10.1002/ijc.22301.
       Full Text  Link to Item
    • Abdelrahim, Maen, Cheryl H. Baker, James L. Abbruzzese, David Sheikh-Hamad, Shengxi Liu, Sung Dae Cho, Kyungsil Yoon, and Stephen Safe. “Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.” Cancer Res 67, no. 7 (April 1, 2007): 3286–94. https://doi.org/10.1158/0008-5472.CAN-06-3831.
       Full Text  Link to Item
    • Li, Donghui, Rena Sue Day, Melissa L. Bondy, Rashmi Sinha, Nga T. Nguyen, Douglas B. Evans, James L. Abbruzzese, and Manal M. Hassan. “Dietary mutagen exposure and risk of pancreatic cancer.” Cancer Epidemiol Biomarkers Prev 16, no. 4 (April 2007): 655–61. https://doi.org/10.1158/1055-9965.EPI-06-0993.
       Full Text  Link to Item
    • Jiao, Li, Ping Chang, Pervez F. Firozi, Dejian Lai, James L. Abbruzzese, and Donghui Li. “Polymorphisms of phase II xenobiotic-metabolizing and DNA repair genes and in vitro N-ethyl-N-nitrosourea-induced O6-ethylguanine levels in human lymphocytes.” Mutat Res 627, no. 2 (March 5, 2007): 146–57. https://doi.org/10.1016/j.mrgentox.2006.11.001.
       Full Text  Link to Item
    • Aloia, Thomas A., Jeffrey E. Lee, Jean-Nicolas Vauthey, Eddie K. Abdalla, Robert A. Wolff, Gauri R. Varadhachary, James L. Abbruzzese, Christopher H. Crane, Douglas B. Evans, and Peter W. T. Pisters. “Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?” J Am Coll Surg 204, no. 3 (March 2007): 347–55. https://doi.org/10.1016/j.jamcollsurg.2006.12.011.
       Full Text  Link to Item
    • Jiao, Li, Melissa L. Bondy, Manal M. Hassan, David Z. Chang, James L. Abbruzzese, Douglas B. Evans, Michael H. Smolensky, and Donghui Li. “Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer.” Cancer 109, no. 5 (March 1, 2007): 840–48. https://doi.org/10.1002/cncr.22468.
       Full Text  Link to Item
    • Banerjee, Sanjeev, Yuxiang Zhang, Zhiwei Wang, Mingxin Che, Paul J. Chiao, James L. Abbruzzese, and Fazlul H. Sarkar. “In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer.” Int J Cancer 120, no. 4 (February 15, 2007): 906–17. https://doi.org/10.1002/ijc.22332.
       Full Text  Link to Item
    • Jiao, Li, Manal M. Hassan, Melissa L. Bondy, James L. Abbruzzese, Douglas B. Evans, and Donghui Li. “The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.” Cancer Lett 245, no. 1–2 (January 8, 2007): 61–68. https://doi.org/10.1016/j.canlet.2005.12.026.
       Full Text  Link to Item
    • Jiao, Li, Jijiang Zhu, Manal M. Hassan, Douglas B. Evans, James L. Abbruzzese, and Donghui Li. “K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.” Pancreas 34, no. 1 (January 2007): 55–62. https://doi.org/10.1097/01.mpa.0000246665.68869.d4.
       Full Text  Link to Item
    • Pentz, Rebecca D., Anne L. Flamm, Jeremy Sugarman, Marlene Z. Cohen, Zhiheng Xu, Roy S. Herbst, and James L. Abbruzzese. “Who should go first in trials with scarce agents? The views of potential participants.” Irb 29, no. 4 (2007): 1–6.
       Link to Item
    • Yao, James C., Jun X. Zhang, Asif Rashid, Sai-Ching J. Yeung, Janio Szklaruk, Kenneth Hess, Keping Xie, Lee Ellis, James L. Abbruzzese, and Jaffer A. Ajani. “Clinical and in vitro studies of imatinib in advanced carcinoid tumors.” Clin Cancer Res 13, no. 1 (January 1, 2007): 234–40. https://doi.org/10.1158/1078-0432.CCR-06-1618.
       Full Text  Link to Item
    • Krishnan, Sunil, Vishal Rana, Nora A. Janjan, James L. Abbruzzese, Morris S. Gould, Prajnan Das, Marc E. Delclos, et al. “Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.” Cancer 107, no. 11 (December 1, 2006): 2589–96. https://doi.org/10.1002/cncr.22328.
       Full Text  Link to Item
    • Doroshow, James H., Sheryl McCoy, John S. Macdonald, Brian F. Issell, Taral Patel, Patrick W. Cobb, Kathleen J. Yost, and James L. Abbruzzese. “Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.” Invest New Drugs 24, no. 6 (November 2006): 537–42. https://doi.org/10.1007/s10637-006-9244-8.
       Full Text  Link to Item
    • El-Rayes, Basil F., Shadan Ali, Ifrah F. Ali, Philip A. Philip, James Abbruzzese, and Fazlul H. Sarkar. “Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.” Cancer Res 66, no. 21 (November 1, 2006): 10553–59. https://doi.org/10.1158/0008-5472.CAN-06-2333.
       Full Text  Link to Item
    • Tsuda, Naotake, Satoshi Ishiyama, Yufeng Li, Constantin G. Ioannides, James L. Abbruzzese, and David Z. Chang. “Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells.” Clin Cancer Res 12, no. 21 (November 1, 2006): 6557–64. https://doi.org/10.1158/1078-0432.CCR-06-0588.
       Full Text  Link to Item
    • Whitehead, Robert P., Sheryl McCoy, Saul E. Rivkin, Howard M. Gross, Marcel E. Conrad, Gary C. Doolittle, Robert A. Wolff, J Wendall Goodwin, Shaker R. Dakhil, and James L. Abbruzzese. “A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.” Invest New Drugs 24, no. 6 (November 2006): 515–20. https://doi.org/10.1007/s10637-006-8440-x.
       Full Text  Link to Item
    • Das, Prajnan, Robert A. Wolff, James L. Abbruzzese, Gauri R. Varadhachary, Douglas B. Evans, Jean Nicolas Vauthey, Andrew Baschnagel, et al. “Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.” Radiat Oncol 1 (October 24, 2006): 41. https://doi.org/10.1186/1748-717X-1-41.
       Full Text  Link to Item
    • Dragovich, Tomislav, Sheryl McCoy, Cecilia M. Fenoglio-Preiser, Jiang Wang, Jacqueline K. Benedetti, Amanda F. Baker, Christopher B. Hackett, et al. “Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.” J Clin Oncol 24, no. 30 (October 20, 2006): 4922–27. https://doi.org/10.1200/JCO.2006.07.1316.
       Full Text  Link to Item
    • Trent, Jonathan C., Latha Ramdas, Jheri Dupart, Kelly Hunt, Homer Macapinlac, Ellen Taylor, Limei Hu, et al. “Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.” Cancer 107, no. 8 (October 15, 2006): 1898–1908. https://doi.org/10.1002/cncr.22214.
       Full Text  Link to Item
    • Hong, David S., James L. Abbruzzese, Karla Bogaard, Yvonne Lassere, Masakazu Fukushima, Akira Mita, Keizo Kuwata, and Paulo M. Hoff. “Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.” Cancer 107, no. 6 (September 15, 2006): 1383–90. https://doi.org/10.1002/cncr.22125.
       Full Text  Link to Item
    • Soliman, Amr S., Melissa Bondy, Charity Renee Webb, David Schottenfeld, Joseph Bonner, Nabih El-Ghawalby, Ahmed Soultan, et al. “Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.” Int J Cancer 119, no. 6 (September 15, 2006): 1455–61. https://doi.org/10.1002/ijc.21986.
       Full Text  Link to Item
    • Khanbolooki, Sanaz, Steffan T. Nawrocki, Thiruvengadam Arumugam, Robert Andtbacka, Maria S. Pino, Razelle Kurzrock, Craig D. Logsdon, James L. Abbruzzese, and David J. McConkey. “Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.” Mol Cancer Ther 5, no. 9 (September 2006): 2251–60. https://doi.org/10.1158/1535-7163.MCT-06-0075.
       Full Text  Link to Item
    • Varadhachary, Gauri R., Eric P. Tamm, James L. Abbruzzese, Henry Q. Xiong, Christopher H. Crane, Huamin Wang, Jeffrey E. Lee, Peter W. T. Pisters, Douglas B. Evans, and Robert A. Wolff. “Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.” Ann Surg Oncol 13, no. 8 (August 2006): 1035–46. https://doi.org/10.1245/ASO.2006.08.011.
       Full Text  Link to Item
    • Wang, Zhiwei, Radha Sengupta, Sanjeev Banerjee, Yiwei Li, Yuxiang Zhang, KM Wahidur Rahman, Amro Aboukameel, et al. “Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.” Cancer Res 66, no. 15 (August 1, 2006): 7653–60. https://doi.org/10.1158/0008-5472.CAN-06-1019.
       Full Text  Link to Item
    • Soliman, A. S., X. Wang, J. -. D. Stanley, N. El-Ghawalby, M. L. Bondy, F. Ezzat, A. Soultan, et al. “Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt.” Arch Environ Contam Toxicol 51, no. 1 (July 2006): 142–48. https://doi.org/10.1007/s00244-005-0154-0.
       Full Text  Link to Item
    • Whitehead, Robert P., Sheryl McCoy, John S. Macdonald, Saul E. Rivkin, Marcus A. Neubauer, Shaker R. Dakhil, Heinz-Josef Lenz, Michael S. Tanaka, James L. Abbruzzese, and James L. Southwest Oncology Group. “Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.” Invest New Drugs 24, no. 4 (July 2006): 335–41. https://doi.org/10.1007/s10637-005-4345-3.
       Full Text  Link to Item
    • Abdelrahim, Maen, Cheryl H. Baker, James L. Abbruzzese, and Stephen Safe. “Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.” J Natl Cancer Inst 98, no. 12 (June 21, 2006): 855–68. https://doi.org/10.1093/jnci/djj232.
       Full Text  Link to Item
    • Ratain, Mark J., Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, et al. “Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.” J Clin Oncol 24, no. 16 (June 1, 2006): 2505–12. https://doi.org/10.1200/JCO.2005.03.6723.
       Full Text  Link to Item
    • Li, Zheng, Qingqing Ding, Yan Li, Stephanie A. Miller, James L. Abbruzzese, and Mien-Chie Hung. “Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant.” Cancer Lett 236, no. 1 (May 8, 2006): 58–63. https://doi.org/10.1016/j.canlet.2005.05.001.
       Full Text  Link to Item
    • Li, Donghui, Marsha Frazier, Douglas B. Evans, Kenneth R. Hess, Christopher H. Crane, Li Jiao, and James L. Abbruzzese. “Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.” J Clin Oncol 24, no. 11 (April 10, 2006): 1720–28. https://doi.org/10.1200/JCO.2005.04.4206.
       Full Text  Link to Item
    • Hess, Kenneth R., Gauri R. Varadhachary, Sarah H. Taylor, Wei Wei, Martin N. Raber, Renato Lenzi, and James L. Abbruzzese. “Metastatic patterns in adenocarcinoma.” Cancer 106, no. 7 (April 1, 2006): 1624–33. https://doi.org/10.1002/cncr.21778.
       Full Text  Link to Item
    • Nawrocki, Steffan T., Jennifer S. Carew, Maria S. Pino, Ralph A. Highshaw, Robert H. I. Andtbacka, Kenneth Dunner, Ashutosh Pal, et al. “Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.” Cancer Res 66, no. 7 (April 1, 2006): 3773–81. https://doi.org/10.1158/0008-5472.CAN-05-2961.
       Full Text  Link to Item
    • Person, Maria D., Jianjun Shen, Angelina Traner, Sean C. Hensley, Herng-Hsiang Lo, James L. Abbruzzese, and Donghui Li. “Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF.” J Biomol Tech 17, no. 2 (April 2006): 145–56.
       Link to Item
    • Pino, Maria S., Marissa Shrader, Cheryl H. Baker, Francesco Cognetti, Henry Q. Xiong, James L. Abbruzzese, and David J. McConkey. “Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.” Cancer Res 66, no. 7 (April 1, 2006): 3802–12. https://doi.org/10.1158/0008-5472.CAN-05-3753.
       Full Text  Link to Item
    • Raut, Chandrajit P., Karen R. Cleary, Gregg A. Staerkel, James L. Abbruzzese, Robert A. Wolff, Jeffrey H. Lee, Jean-Nicolas Vauthey, Jeffrey E. Lee, Peter W. T. Pisters, and Douglas B. Evans. “Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival.” Ann Surg Oncol 13, no. 4 (April 2006): 582–94. https://doi.org/10.1245/ASO.2006.05.002.
       Full Text  Link to Item
    • Williamson, Stephen K., Sheryl A. McCoy, David R. Gandara, Shaker R. Dakhil, Kathleen J. Yost, Jorge C. Paradelo, James N. Atkins, Charles D. Blanke, James L. Abbruzzese, and James L. Southwest Oncology Group (SWOG). “Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.” Am J Clin Oncol 29, no. 2 (April 2006): 116–22. https://doi.org/10.1097/01.coc.0000199883.10685.2b.
       Full Text  Link to Item
    • Abbruzzese, J. L. “Introducing CCR practice of translational oncology.” Clinical Cancer Research 12, no. 6 (March 15, 2006): 1657. https://doi.org/10.1158/1078-0432.CCR-06-0403.
       Full Text
    • Li, Donghui, Hui Liu, Li Jiao, David Z. Chang, Garth Beinart, Robert A. Wolff, Douglas B. Evans, Manal M. Hassan, and James L. Abbruzzese. “Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.” Cancer Res 66, no. 6 (March 15, 2006): 3323–30. https://doi.org/10.1158/0008-5472.CAN-05-3032.
       Full Text  Link to Item
    • Crane, Christopher H., Lee M. Ellis, James L. Abbruzzese, Christina Amos, Henry Q. Xiong, Linus Ho, Douglas B. Evans, et al. “Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.” J Clin Oncol 24, no. 7 (March 1, 2006): 1145–51. https://doi.org/10.1200/JCO.2005.03.6780.
       Full Text  Link to Item
    • Trevino, Jose G., Justin M. Summy, Donald P. Lesslie, Nila U. Parikh, David S. Hong, Francis Y. Lee, Nicholas J. Donato, James L. Abbruzzese, Cheryl H. Baker, and Gary E. Gallick. “Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.” Am J Pathol 168, no. 3 (March 2006): 962–72. https://doi.org/10.2353/ajpath.2006.050570.
       Full Text  Link to Item
    • Hoff, Paulo M., Robert A. Wolff, Karla Bogaard, Sherry Waldrum, and James L. Abbruzzese. “A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.” Jpn J Clin Oncol 36, no. 2 (February 2006): 100–103. https://doi.org/10.1093/jjco/hyi229.
       Full Text  Link to Item
    • Zhang, Yuxiang, Sanjeev Banerjee, Zhiwei Wang, Hu Xu, Liyue Zhang, Ramzi Mohammad, Amro Aboukameel, et al. “Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer.” Cancer Res 66, no. 2 (January 15, 2006): 1025–32. https://doi.org/10.1158/0008-5472.CAN-05-2968.
       Full Text  Link to Item
    • Jiao, Li, Melissa L. Bondy, Manal M. Hassan, Robert A. Wolff, Douglas B. Evans, James L. Abbruzzese, and Donghui Li. “Selected polymorphisms of DNA repair genes and risk of pancreatic cancer.” Cancer Detect Prev 30, no. 3 (2006): 284–91. https://doi.org/10.1016/j.cdp.2006.05.002.
       Full Text  Link to Item
    • Kriegel, Alison M., Amr S. Soliman, Qing Zhang, Nabih El-Ghawalby, Farouk Ezzat, Ahmed Soultan, Mohamed Abdel-Wahab, et al. “Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt.” Environ Health Perspect 114, no. 1 (January 2006): 113–19. https://doi.org/10.1289/ehp.8035.
       Full Text  Link to Item
    • Li, Donghui, Li Jiao, Yanan Li, Mark A. Doll, David W. Hein, Melissa L. Bondy, Douglas B. Evans, et al. “Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.” Carcinogenesis 27, no. 1 (January 2006): 103–11. https://doi.org/10.1093/carcin/bgi171.
       Full Text  Link to Item
    • Soliman, Amr S., Qing Zhang, Thanaa Saleh, Ali Zarzour, Mohei Selim, Mahmoud Abdel-Fattah, and James L. Abbruzzese. “Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates.” Cancer Detect Prev 30, no. 5 (2006): 473–79. https://doi.org/10.1016/j.cdp.2006.06.006.
       Full Text  Link to Item
    • Xiong, Henry Q., Kelli Carr, and James L. Abbruzzese. “Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.” Drugs 66, no. 8 (2006): 1059–72. https://doi.org/10.2165/00003495-200666080-00003.
       Full Text  Link to Item
    • Zhu, J., A. Rashid, K. Cleary, J. L. Abbruzzese, H. Friess, S. Takahashi, T. Shirai, and D. Li. “Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues.” Biomarkers 11, no. 4 (2006): 319–28. https://doi.org/10.1080/13547500600667911.
       Full Text  Link to Item
    • Nawrocki, Steffan T., Jennifer S. Carew, Kenneth Dunner, Lawrence H. Boise, Paul J. Chiao, Peng Huang, James L. Abbruzzese, and David J. McConkey. “Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.” Cancer Res 65, no. 24 (December 15, 2005): 11510–19. https://doi.org/10.1158/0008-5472.CAN-05-2394.
       Full Text  Link to Item
    • Nawrocki, Steffan T., Jennifer S. Carew, Maria S. Pino, Ralph A. Highshaw, Kenneth Dunner, Peng Huang, James L. Abbruzzese, and David J. McConkey. “Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.” Cancer Res 65, no. 24 (December 15, 2005): 11658–66. https://doi.org/10.1158/0008-5472.CAN-05-2370.
       Full Text  Link to Item
    • Yokoi, Kenji, Takamitsu Sasaki, Corazon D. Bucana, Dominic Fan, Cheryl H. Baker, Yasuhiko Kitadai, Toshio Kuwai, James L. Abbruzzese, and Isaiah J. Fidler. “Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.” Cancer Res 65, no. 22 (November 15, 2005): 10371–80. https://doi.org/10.1158/0008-5472.CAN-05-1698.
       Full Text  Link to Item
    • Thomas, Melanie B., and James L. Abbruzzese. “Opportunities for targeted therapies in hepatocellular carcinoma.” J Clin Oncol 23, no. 31 (November 1, 2005): 8093–8108. https://doi.org/10.1200/JCO.2004.00.1537.
       Full Text  Link to Item
    • Yokoi, Kenji, Li-Chen Nancy Shih, Ryuji Kobayashi, John Koomen, David Hawke, Donghui Li, Stanley R. Hamilton, James L. Abbruzzese, Kevin R. Coombes, and Isaiah J. Fidler. “Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.” Int J Oncol 27, no. 5 (November 2005): 1361–69.
       Link to Item
    • Zhang, Qian, Jiang Li, Michael Deavers, James L. Abbruzzese, and Linus Ho. “The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells.” J Histochem Cytochem 53, no. 11 (November 2005): 1371–82. https://doi.org/10.1369/jhc.4A6508.2005.
       Full Text  Link to Item
    • Freedland, Stephen J., William B. Isaacs, Elizabeth A. Platz, Martha K. Terris, William J. Aronson, Christopher L. Amling, Joseph C. Presti, and Christopher J. Kane. “Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.” J Clin Oncol 23, no. 30 (October 20, 2005): 7546–54. https://doi.org/10.1200/JCO.2005.05.525.
       Full Text  Link to Item
    • Asano, Takayuki, Yixin Yao, Sonyo Shin, James McCubrey, James L. Abbruzzese, and Shrikanth A. G. Reddy. “Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.” Cancer Res 65, no. 20 (October 15, 2005): 9164–68. https://doi.org/10.1158/0008-5472.CAN-05-0779.
       Full Text  Link to Item
    • Banerjee, Sanjeev, Yuxiang Zhang, Shadan Ali, Mohammad Bhuiyan, Zhiwei Wang, Paul J. Chiao, Philip A. Philip, James Abbruzzese, and Fazlul H. Sarkar. “Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.” Cancer Res 65, no. 19 (October 1, 2005): 9064–72. https://doi.org/10.1158/0008-5472.CAN-05-1330.
       Full Text  Link to Item
    • Kindler, Hedy L., Peter K. Tothy, Robert Wolff, Richard A. McCormack, James L. Abbruzzese, Sridhar Mani, Kurombi T. Wade-Oliver, and Everett E. Vokes. “Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.” Invest New Drugs 23, no. 5 (October 2005): 489–93. https://doi.org/10.1007/s10637-005-2909-x.
       Full Text  Link to Item
    • Macdonald, John S., Sheryl McCoy, Robert P. Whitehead, Syma Iqbal, James L. Wade, Jeffrey K. Giguere, and James L. Abbruzzese. “A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.” Invest New Drugs 23, no. 5 (October 2005): 485–87. https://doi.org/10.1007/s10637-005-2908-y.
       Full Text  Link to Item
    • Ko, A. H., J. Hwang, A. P. Venook, J. L. Abbruzzese, E. K. Bergsland, and M. A. Tempero. “Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.” Br J Cancer 93, no. 2 (July 25, 2005): 195–99. https://doi.org/10.1038/sj.bjc.6602687.
       Full Text  Link to Item
    • Yokoi, Kenji, Sun-Jin Kim, Premal Thaker, Sertac Yazici, Do-Hyun Nam, Junqin He, Takamitsu Sasaki, et al. “Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.” Neoplasia 7, no. 7 (July 2005): 696–704. https://doi.org/10.1593/neo.05193.
       Full Text  Link to Item
    • Asano, T., Y. Yao, J. Zhu, D. Li, J. L. Abbruzzese, and S. A. G. Reddy. “Erratum: The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells (Oncogene (2004) 23 (8571-8580) DOI: 10.1038/sj.onc.1207902).” Oncogene 24, no. 26 (June 16, 2005): 4320. https://doi.org/10.1038/sj.onc.1208766.
       Full Text
    • Sclabas, Guido M., Tadashi Uwagawa, Christian Schmidt, Kenneth R. Hess, Douglas B. Evans, James L. Abbruzzese, and Paul J. Chiao. “Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin.” Cancer 103, no. 12 (June 15, 2005): 2485–90. https://doi.org/10.1002/cncr.21075.
       Full Text  Link to Item
    • Li, Donghui, Maha Ahmed, Yanan Li, Li Jiao, Ta-Hsu Chou, Robert A. Wolff, Renato Lenzi, et al. “5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer.” Cancer Epidemiol Biomarkers Prev 14, no. 6 (June 2005): 1470–76. https://doi.org/10.1158/1055-9965.EPI-04-0894.
       Full Text  Link to Item
    • Wong, Adrian A., Mark E. Delclos, Robert A. Wolff, Douglas B. Evans, James L. Abbruzzese, Eric P. Tamm, Henry Q. Xiong, Linus Ho, Christopher H. Crane, and Christopher H. Pancreatic Tumor Study Group. “Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.” Am J Clin Oncol 28, no. 3 (June 2005): 227–33. https://doi.org/10.1097/01.coc.0000145290.06582.c3.
       Full Text  Link to Item
    • Xiong, Henry Q., William Plunkett, Robert Wolff, Min Du, Renato Lenzi, and James L. Abbruzzese. “A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.” Cancer Chemother Pharmacol 55, no. 6 (June 2005): 559–64. https://doi.org/10.1007/s00280-004-0916-9.
       Full Text  Link to Item
    • Asano, Takayuki, Yixin Yao, Jijiang Zhu, Donghui Li, James L. Abbruzzese, and Shrikanth A. Reddy. “The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.” Biochem Biophys Res Commun 331, no. 1 (May 27, 2005): 295–302. https://doi.org/10.1016/j.bbrc.2005.03.166.
       Full Text  Link to Item
    • Chang, David Z., and James L. Abbruzzese. “Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.” Clin Adv Hematol Oncol 3, no. 5 (May 2005): 400–404.
       Link to Item
    • Yokoi, Kenji, Premal H. Thaker, Sertac Yazici, Robert R. Rebhun, Do-Hyun Nam, Junqin He, Sun-Jin Kim, James L. Abbruzzese, Stanley R. Hamilton, and Isaiah J. Fidler. “Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.” Cancer Res 65, no. 9 (May 1, 2005): 3716–25. https://doi.org/10.1158/0008-5472.CAN-04-3700.
       Full Text  Link to Item
    • Zhu, Jijiang, James L. Abbruzzese, Julie Izzo, Walter N. Hittelman, and Donghui Li. “AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells.” Cancer Genet Cytogenet 159, no. 1 (May 2005): 10–17. https://doi.org/10.1016/j.cancergencyto.2004.09.008.
       Full Text  Link to Item
    • Patt, Yehuda Z., Manal M. Hassan, Richard D. Lozano, Ajay K. Nooka, Isaac I. Schnirer, Jerome B. Zeldis, James L. Abbruzzese, and Thomas D. Brown. “Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.” Cancer 103, no. 4 (February 15, 2005): 749–55. https://doi.org/10.1002/cncr.20821.
       Full Text  Link to Item
    • Koomen, John M., Lichen Nancy Shih, Kevin R. Coombes, Donghui Li, Lian-chun Xiao, Isaiah J. Fidler, James L. Abbruzzese, and Ryuji Kobayashi. “Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins.” Clin Cancer Res 11, no. 3 (February 1, 2005): 1110–18.
       Link to Item
    • Sclabas, Guido M., Shuichi Fujioka, Christian Schmidt, Zhongkui Li, Wayne A. I. Frederick, Wentao Yang, Kenji Yokoi, et al. “Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.” Clin Cancer Res 11, no. 2 Pt 1 (January 15, 2005): 440–49.
       Link to Item
    • Davis, Darren W., Ryan Takamori, Chandrajit P. Raut, Henry Q. Xiong, Roy S. Herbst, Walter M. Stadler, John V. Heymach, et al. “Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.” Clin Cancer Res 11, no. 2 Pt 1 (January 15, 2005): 678–89.
       Link to Item
    • Cao, D., R. E. Wilentz, J. L. Abbruzzese, L. Ho, and A. Maitra. “Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.” International Journal of Gastrointestinal Cancer 36, no. 1 (2005): 39–46.
    • Cao, Dengfeng, Robb E. Wilentz, James L. Abbruzzese, Linus Ho, and Anirban Maitra. “Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.” Int J Gastrointest Cancer 36, no. 1 (2005): 39–46. https://doi.org/10.1385/IJGC:36:1:039.
       Full Text  Link to Item
    • Davis, D. W., R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, et al. “Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.” Clinical Cancer Research 11, no. 2 I (2005): 678–89.
    • Sclabas, G. M., S. Fujioka, C. Schmidt, Z. Li, W. A. I. Frederick, W. Yang, K. Yokoi, et al. “Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.” Clinical Cancer Research 11, no. 2 I (2005): 440–49.
    • Koomen, John M., Donghui Li, Lian-chun Xiao, Thomas C. Liu, Kevin R. Coombes, James Abbruzzese, and Ryuji Kobayashi. “Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.” J Proteome Res 4, no. 3 (2005): 972–81. https://doi.org/10.1021/pr050046x.
       Full Text  Link to Item
    • Koomen, John M., Haitao Zhao, Donghui Li, Waleed Nasser, David H. Hawke, James L. Abbruzzese, Keith A. Baggerly, and Ryuji Kobayashi. “Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting.” Rapid Commun Mass Spectrom 19, no. 12 (2005): 1624–36. https://doi.org/10.1002/rcm.1963.
       Full Text  Link to Item
    • Ebrahimi, Behnam, Susan L. Tucker, Donghui Li, James L. Abbruzzese, and Razelle Kurzrock. “Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.” Cancer 101, no. 12 (December 15, 2004): 2727–36. https://doi.org/10.1002/cncr.20672.
       Full Text  Link to Item
    • Shen, Jianjun, Maria D. Person, Jijiang Zhu, James L. Abbruzzese, and Donghui Li. “Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.” Cancer Res 64, no. 24 (December 15, 2004): 9018–26. https://doi.org/10.1158/0008-5472.CAN-04-3262.
       Full Text  Link to Item
    • Li, Lan, Bharat B. Aggarwal, Shishir Shishodia, James Abbruzzese, and Razelle Kurzrock. “Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.” Cancer 101, no. 10 (November 15, 2004): 2351–62. https://doi.org/10.1002/cncr.20605.
       Full Text  Link to Item
    • Asano, Takayuki, Yixin Yao, Jijiang Zhu, Donghui Li, James L. Abbruzzese, and Shrikanth A. G. Reddy. “The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.” Oncogene 23, no. 53 (November 11, 2004): 8571–80. https://doi.org/10.1038/sj.onc.1207902.
       Full Text  Link to Item
    • Whitehead, Robert P., Jacqueline K. Benedetti, James L. Abbruzzese, Bach Ardalan, Stephen Williamson, Ellen R. Gaynor, Stanley P. Balcerzak, and John S. Macdonald. “A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.” Invest New Drugs 22, no. 4 (November 2004): 467–73. https://doi.org/10.1023/B:DRUG.0000036689.28596.c6.
       Full Text  Link to Item
    • Xiong, Henry Q., Roy Herbst, Silvana C. Faria, Catherine Scholz, Darren Davis, Edward F. Jackson, Timothy Madden, et al. “A phase I surrogate endpoint study of SU6668 in patients with solid tumors.” Invest New Drugs 22, no. 4 (November 2004): 459–66. https://doi.org/10.1023/B:DRUG.0000036688.96453.8d.
       Full Text  Link to Item
    • Abbruzzese, James L., and Scott M. Lippman. “The convergence of cancer prevention and therapy in early-phase clinical drug development.” Cancer Cell 6, no. 4 (October 2004): 321–26. https://doi.org/10.1016/j.ccr.2004.09.021.
       Full Text  Link to Item
    • Jafari, Mehrdad, and James L. Abbruzzese. “Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force.” Surg Oncol Clin N Am 13, no. 4 (October 2004): 751–xi. https://doi.org/10.1016/j.soc.2004.06.009.
       Full Text  Link to Item
    • Wang, Wei, Shi Ke, Qingping Wu, Chusilp Charnsangavej, Mikhail Gurfinkel, Juri G. Gelovani, James L. Abbruzzese, Eva M. Sevick-Muraca, and Chun Li. “Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts.” Mol Imaging 3, no. 4 (October 2004): 343–51. https://doi.org/10.1162/15353500200404148.
       Full Text  Link to Item
    • Xiong, Henry Q., and James L. Abbruzzese. “Adjuvant therapy for pancreatic cancer: current status and future directions.” Surg Oncol Clin N Am 13, no. 4 (October 2004): 737–xi. https://doi.org/10.1016/j.soc.2004.06.010.
       Full Text  Link to Item
    • Eng, Cathy, and James L. Abbruzzese. “The treatment of colorectal carcinoma: standard chemotherapy and beyond.” Clin Adv Hematol Oncol 2, no. 9 (September 2004): 592–98.
       Link to Item
    • Fujioka, Shuichi, Jiangong Niu, Christian Schmidt, Guido M. Sclabas, Bailu Peng, Tadashi Uwagawa, Zhongkui Li, Douglas B. Evans, James L. Abbruzzese, and Paul J. Chiao. “NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.” Mol Cell Biol 24, no. 17 (September 2004): 7806–19. https://doi.org/10.1128/MCB.24.17.7806-7819.2004.
       Full Text  Link to Item
    • Shirao, K., P. M. Hoff, A. Ohtsu, P. J. Loehrer, I. Hyodo, S. Wadler, R. G. Wadleigh, et al. “Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.” J Clin Oncol 22, no. 17 (September 1, 2004): 3466–74. https://doi.org/10.1200/JCO.2004.05.017.
       Full Text  Link to Item
    • Hoff, Paulo M., Everardo D. Saad, Richard Pazdur, Robert Wolff, Yvonne Lassere, Karla R. Bogaard, and James L. Abbruzzese. “Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.” Invest New Drugs 22, no. 3 (August 2004): 307–13. https://doi.org/10.1023/B:DRUG.0000026257.31142.41.
       Full Text  Link to Item
    • Whitehead, Robert P., Jacqueline K. Benedetti, James L. Abbruzzese, Bach Ardalan, J Wendall Goodwin, Stanley P. Balcerzak, Wolfram E. Samlowski, Heinz-Josef Lenz, and John S. Macdonald. “A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.” Invest New Drugs 22, no. 3 (August 2004): 335–41. https://doi.org/10.1023/B:DRUG.0000026261.76197.54.
       Full Text  Link to Item
    • Davis, Darren W., Keiji Inoue, Colin P. N. Dinney, Daniel J. Hicklin, James L. Abbruzzese, and David J. McConkey. “Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.” Cancer Res 64, no. 13 (July 1, 2004): 4601–10. https://doi.org/10.1158/0008-5472.CAN-2879-2.
       Full Text  Link to Item
    • Li, Zhongkui, Guido M. Sclabas, Bailu Peng, Kenneth R. Hess, James L. Abbruzzese, Douglas B. Evans, and Paul J. Chiao. “Overexpression of synuclein-gamma in pancreatic adenocarcinoma.” Cancer 101, no. 1 (July 1, 2004): 58–65. https://doi.org/10.1002/cncr.20321.
       Full Text  Link to Item
    • Xiong, Henry Q., Arthur Rosenberg, Albert LoBuglio, William Schmidt, Robert A. Wolff, John Deutsch, Michael Needle, and James L. Abbruzzese. “Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.” J Clin Oncol 22, no. 13 (July 1, 2004): 2610–16. https://doi.org/10.1200/JCO.2004.12.040.
       Full Text  Link to Item
    • Fujioka, Shuichi, Christian Schmidt, Guido M. Sclabas, Zhongkui Li, Hélène Pelicano, Bailu Peng, Alice Yao, et al. “Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.” J Biol Chem 279, no. 26 (June 25, 2004): 27549–59. https://doi.org/10.1074/jbc.M313435200.
       Full Text  Link to Item
    • Hoff, Paulo M., Richard Pazdur, Yvonne Lassere, Susan Carter, Dvorit Samid, Diane Polito, and James L. Abbruzzese. “Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.” J Clin Oncol 22, no. 11 (June 1, 2004): 2078–83. https://doi.org/10.1200/JCO.2004.05.072.
       Full Text  Link to Item
    • Hoff, Paulo M., Lee M. Ellis, and James L. Abbruzzese. “Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?” Oncology (Williston Park) 18, no. 6 (May 2004): 736–41.
       Link to Item
    • Pino, Simona M., Henry Q. Xiong, David McConkey, and James L. Abbruzzese. “Novel therapies for pancreatic adenocarcinoma.” Curr Oncol Rep 6, no. 3 (May 2004): 199–206. https://doi.org/10.1007/s11912-004-0050-1.
       Full Text  Link to Item
    • Varadhachary, Gauri R., James L. Abbruzzese, and Renato Lenzi. “Diagnostic strategies for unknown primary cancer.” Cancer 100, no. 9 (May 1, 2004): 1776–85. https://doi.org/10.1002/cncr.20202.
       Full Text  Link to Item
    • Eng, Cathy, James Abbruzzese, and Bruce D. Minsky. “Chemotherapy and radiation of anal canal cancer: the first approach.” Surg Oncol Clin N Am 13, no. 2 (April 2004): 309–viii. https://doi.org/10.1016/j.soc.2003.12.004.
       Full Text  Link to Item
    • Pino, Simona M., Henry Q. Xiong, David McConkey, and James L. Abbruzzese. “Novel therapies for pancreatic adenocarcinoma.” Curr Gastroenterol Rep 6, no. 2 (April 2004): 119–25. https://doi.org/10.1007/s11894-004-0038-x.
       Full Text  Link to Item
    • Wei, Daoyan, Liwei Wang, Yanjuan He, Henry Q. Xiong, James L. Abbruzzese, and Keping Xie. “Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.” Cancer Res 64, no. 6 (March 15, 2004): 2030–38. https://doi.org/10.1158/0008-5472.can-03-1945.
       Full Text  Link to Item
    • Xiong, H. Q., J. L. Abbruzzese, E. Lin, L. Wang, L. Zheng, and K. Xie. “NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.” International Journal of Cancer 108, no. 2 (January 10, 2004): 181–88. https://doi.org/10.1002/ijc.11562.
       Full Text
    • Ke, Shi, Xiaoxia Wen, Qing-Ping Wu, Sidney Wallace, Chusilp Charnsangavej, Anne M. Stachowiak, Clifton L. Stephens, James L. Abbruzzese, Donald A. Podoloff, and Chun Li. “Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V.” J Nucl Med 45, no. 1 (January 2004): 108–15.
       Link to Item
    • Davis, Darren W., Yu Shen, Nizar A. Mullani, Sijin Wen, Roy S. Herbst, Michael O’Reilly, James L. Abbruzzese, and David J. McConkey. “Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.” Clin Cancer Res 10, no. 1 Pt 1 (January 1, 2004): 33–42. https://doi.org/10.1158/1078-0432.ccr-0736-3.
       Full Text  Link to Item
    • Jiang, Yixing, Liwei Wang, Weida Gong, Daoyan Wei, Xiangdong Le, James Yao, Jaffer Ajani, James L. Abbruzzese, Suyun Huang, and Keping Xie. “A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer.” Clin Exp Metastasis 21, no. 8 (2004): 755–64. https://doi.org/10.1007/s10585-005-1198-2.
       Full Text  Link to Item
    • Koomen, John M., Haitao Zhao, Donghui Li, James Abbruzzese, Keith Baggerly, and Ryuji Kobayashi. “Diagnostic protein discovery using proteolytic peptide targeting and identification.” Rapid Commun Mass Spectrom 18, no. 21 (2004): 2537–48. https://doi.org/10.1002/rcm.1657.
       Full Text  Link to Item
    • Urba, Susan G., Kari Chansky, Peter J. VanVeldhuizen, Robert E. Pluenneke, Jacqueline K. Benedetti, John S. Macdonald, James L. Abbruzzese, and James L. Southwest Oncology Group Study. “Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.” Invest New Drugs 22, no. 1 (January 2004): 91–97. https://doi.org/10.1023/b:drug.0000006179.20974.af.
       Full Text  Link to Item
    • Schmidt, Christian, Bailu Peng, Zhongkui Li, Guido M. Sclabas, Shuichi Fujioka, Jiangong Niu, Marc Schmidt-Supprian, Douglas B. Evans, James L. Abbruzzese, and Paul J. Chiao. “Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation.” Mol Cell 12, no. 5 (November 2003): 1287–1300. https://doi.org/10.1016/s1097-2765(03)00390-3.
       Full Text  Link to Item
    • Chu, David Z. J., Kari Chansky, David S. Alberts, Frank L. Meyskens, Cecilia M. Fenoglio-Preiser, Saul E. Rivkin, Glenn M. Mills, et al. “Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study.” Ann Surg Oncol 10, no. 8 (October 2003): 870–75. https://doi.org/10.1245/aso.2003.03.037.
       Full Text  Link to Item
    • Xie, Keping, and James L. Abbruzzese. “Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers.” Cancer Cell 4, no. 4 (October 2003): 245–47. https://doi.org/10.1016/s1535-6108(03)00246-0.
       Full Text  Link to Item
    • Tempero, Margaret, William Plunkett, Veronique Ruiz Van Haperen, John Hainsworth, Howard Hochster, Renato Lenzi, and James Abbruzzese. “Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.” J Clin Oncol 21, no. 18 (September 15, 2003): 3402–8. https://doi.org/10.1200/JCO.2003.09.140.
       Full Text  Link to Item
    • Davis, D. W., D. J. McConkey, J. L. Abbruzzese, and R. S. Herbst. “Surrogate markers in antiangiogenesis clinical trials.” Br J Cancer 89, no. 1 (July 7, 2003): 8–14. https://doi.org/10.1038/sj.bjc.6601035.
       Full Text  Link to Item
    • Xiong, Henry Q., Hai T. Tran, Timothy L. Madden, Robert A. Newman, and James L. Abbruzzese. “Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.” Clin Cancer Res 9, no. 6 (June 2003): 2066–71.
       Link to Item
    • Cohen, Steven J., Linus Ho, Sulabha Ranganathan, James L. Abbruzzese, R Katherine Alpaugh, Mary Beard, Nancy L. Lewis, et al. “Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.” J Clin Oncol 21, no. 7 (April 1, 2003): 1301–6. https://doi.org/10.1200/JCO.2003.08.040.
       Full Text  Link to Item
    • Nasta, Sunita Dwivedy, Paulo M. Hoff, Christopher S. George, Marcus Neubauer, Steven C. Cohen, James Abbruzzese, Rodger Winn, and Richard M. Pazdur. “Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer.” Am J Clin Oncol 26, no. 2 (April 2003): 132–34. https://doi.org/10.1097/00000421-200304000-00006.
       Full Text  Link to Item
    • Wang, Bailiang, Daoyan Wei, Vanessa E. Crum, Erica L. Richardson, Henry H. Xiong, Yu Luo, Suyun Huang, James L. Abbruzzese, and Keping Xie. “A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis.” Oncogene 22, no. 12 (March 27, 2003): 1771–82. https://doi.org/10.1038/sj.onc.1206386.
       Full Text  Link to Item
    • Fujioka, Shuichi, Guido M. Sclabas, Christian Schmidt, Jiangong Niu, Wayne A. Frederick, Qiang G. Dong, James L. Abbruzzese, Douglas B. Evans, Cheryl Baker, and Paul J. Chiao. “Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.” Oncogene 22, no. 9 (March 6, 2003): 1365–70. https://doi.org/10.1038/sj.onc.1206323.
       Full Text  Link to Item
    • Li, Donghui, Jijiang Zhu, Pervez F. Firozi, James L. Abbruzzese, Douglas B. Evans, Karen Cleary, Helmut Friess, and Subrata Sen. “Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.” Clin Cancer Res 9, no. 3 (March 2003): 991–97.
       Link to Item
    • Hecht, J Randolph, Rudolph Bedford, James L. Abbruzzese, Sandeep Lahoti, Tony R. Reid, Roy M. Soetikno, David H. Kirn, and Scott M. Freeman. “A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.” Clin Cancer Res 9, no. 2 (February 2003): 555–61.
       Link to Item
    • Wei, Daoyan, Xiangdong Le, Leizhen Zheng, Liwei Wang, Jennifer A. Frey, Allen C. Gao, Zhihai Peng, et al. “Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.” Oncogene 22, no. 3 (January 23, 2003): 319–29. https://doi.org/10.1038/sj.onc.1206122.
       Full Text  Link to Item
    • Fujioka, S., G. M. Sclabas, C. Schmidt, W. A. Frederick, Q. G. Dong, J. L. Abbruzzese, D. B. Evans, C. Baker, and P. J. Chiao. “Function of nuclear factor κB in pancreatic cancer metastasis.” Clinical Cancer Research 9, no. 1 I (2003): 346–54.
    • Fujioka, Shuichi, Guido M. Sclabas, Christian Schmidt, Wayne A. Frederick, Qiang G. Dong, James L. Abbruzzese, Douglas B. Evans, Cheryl Baker, and Paul J. Chiao. “Function of nuclear factor kappaB in pancreatic cancer metastasis.” Clin Cancer Res 9, no. 1 (January 2003): 346–54.
       Link to Item
    • Wei, Daoyan, Henry Q. Xiong, James L. Abbruzzese, and Keping Xie. “Experimental animal models of pancreatic carcinogenesis and metastasis.” Int J Gastrointest Cancer 33, no. 1 (2003): 43–60. https://doi.org/10.1385/IJGC:33:1:43.
       Full Text  Link to Item
    • Abbruzzese, James L. “The challenge of pancreatic cancer.” Int J Gastrointest Cancer 33, no. 1 (2003): 1–2. https://doi.org/10.1385/IJGC:33:1:1.
       Full Text  Link to Item
    • Melichar, Bohuslav, Renato Lenzi, Michael Rosenblum, Andrzej P. Kudelka, John J. Kavanagh, Karolina Melicharova, Stacie Templin, Michael E. Garcia, James L. Abbruzzese, and Ralph S. Freedman. “Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.” J Immunother 26, no. 3 (2003): 270–76. https://doi.org/10.1097/00002371-200305000-00010.
       Full Text  Link to Item
    • Lenzi, Renato, Michael Rosenblum, Claire Verschraegen, Andrzej P. Kudelka, John J. Kavanagh, Marshall E. Hicks, Eric A. Lang, et al. “Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.” Clin Cancer Res 8, no. 12 (December 2002): 3686–95.
       Link to Item
    • Nawrocki, Steffan T., Christiane J. Bruns, Matthew T. Harbison, Richard J. Bold, Bridget Sweeney Gotsch, James L. Abbruzzese, Peter Elliott, Julian Adams, and David J. McConkey. “Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.” Mol Cancer Ther 1, no. 14 (December 2002): 1243–53.
       Link to Item
    • Peng, Bailu, Jason B. Fleming, Tara Breslin, Ana M. Grau, Shuichi Fojioka, James L. Abbruzzese, Douglas B. Evans, et al. “Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.” Clin Cancer Res 8, no. 11 (November 2002): 3628–38.
       Link to Item
    • Reid, Tony, Eva Galanis, James Abbruzzese, Dan Sze, Lawrence M. Wein, James Andrews, Britta Randlev, et al. “Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.” Cancer Res 62, no. 21 (November 1, 2002): 6070–79.
       Link to Item
    • Hassan, Manal M., Lu-Yu Hwang, Chiq J. Hatten, Mark Swaim, Donghui Li, James L. Abbruzzese, Palmer Beasley, and Yehuda Z. Patt. “Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.” Hepatology 36, no. 5 (November 2002): 1206–13. https://doi.org/10.1053/jhep.2002.36780.
       Full Text  Link to Item
    • Leichman, Cynthia G., Kari Chansky, John S. Macdonald, Michael A. Doukas, G Thomas Budd, Jeffrey K. Giguere, James L. Abbruzzese, and James L. Southwest Oncology Group. “Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.” Invest New Drugs 20, no. 4 (November 2002): 419–24. https://doi.org/10.1023/a:1020662113061.
       Full Text  Link to Item
    • Rothenberg, M. L., J. K. Benedetti, J. S. Macdonald, T. E. Seay, M. A. Neubauer, C. S. George, M. S. Tanaka, J. K. Giguere, B. T. Pruitt, and J. L. Abbruzzese. “Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.” Ann Oncol 13, no. 10 (October 2002): 1576–82. https://doi.org/10.1093/annonc/mdf274.
       Full Text  Link to Item
    • Saad, Everardo D., Eric H. Kraut, Paulo M. Hoff, Dennis F. Moore, Donnah Jones, Richard Pazdur, and James L. Abbruzzese. “Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.” Am J Clin Oncol 25, no. 5 (October 2002): 451–53. https://doi.org/10.1097/00000421-200210000-00005.
       Full Text  Link to Item
    • Dong, Qiang G., Guido M. Sclabas, Shuichi Fujioka, Christian Schmidt, Bailu Peng, TianAi Wu, Ming-Sound Tsao, et al. “The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.” Oncogene 21, no. 42 (September 19, 2002): 6510–19. https://doi.org/10.1038/sj.onc.1205848.
       Full Text  Link to Item
    • Pentz, Rebecca D., Anne L. Flamm, Jeremy Sugarman, Marlene Z. Cohen, G. Daniel Ayers, Roy S. Herbst, and James L. Abbruzzese. “Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.” J Clin Oncol 20, no. 18 (September 15, 2002): 3785–91. https://doi.org/10.1200/JCO.2002.04.084.
       Full Text  Link to Item
    • Herbst, Roy S., Kenneth R. Hess, Hai T. Tran, Jennifer E. Tseng, Nizar A. Mullani, Chusilp Charnsangavej, Timothy Madden, et al. “Phase I study of recombinant human endostatin in patients with advanced solid tumors.” J Clin Oncol 20, no. 18 (September 15, 2002): 3792–3803. https://doi.org/10.1200/JCO.2002.11.061.
       Full Text  Link to Item
    • Herbst, Roy S., Nizar A. Mullani, Darren W. Davis, Kenneth R. Hess, David J. McConkey, Chusilp Charnsangavej, Michael S. O’Reilly, et al. “Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.” J Clin Oncol 20, no. 18 (September 15, 2002): 3804–14. https://doi.org/10.1200/JCO.2002.05.102.
       Full Text  Link to Item
    • Lobell, Robert B., Dongming Liu, Carolyn A. Buser, Joseph P. Davide, Elizabeth DePuy, Kelly Hamilton, Kenneth S. Koblan, et al. “Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.” Mol Cancer Ther 1, no. 9 (July 2002): 747–58.
       Link to Item
    • Phillips, R. K. S., M. H. Wallace, P. M. Lynch, E. Hawk, G. B. Gordon, B. P. Saunders, N. Wakabayashi, et al. “A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.” Gut 50, no. 6 (June 2002): 857–60. https://doi.org/10.1136/gut.50.6.857.
       Full Text  Link to Item
    • Pisters, Peter W. T., Robert A. Wolff, Nora A. Janjan, Karen R. Cleary, Chusilp Charnsangavej, Christopher N. Crane, Renato Lenzi, et al. “Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.” J Clin Oncol 20, no. 10 (May 15, 2002): 2537–44. https://doi.org/10.1200/JCO.2002.11.064.
       Full Text  Link to Item
    • Crane, Christopher H., James L. Abbruzzese, Douglas B. Evans, Robert A. Wolff, Mathew T. Ballo, Marc Delclos, Luka Milas, et al. “Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?” Int J Radiat Oncol Biol Phys 52, no. 5 (April 1, 2002): 1293–1302. https://doi.org/10.1016/s0360-3016(01)02740-7.
       Full Text  Link to Item
    • Saad, Everardo D., and James L. Abbruzzese. “Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.” Crit Rev Oncol Hematol 41, no. 2 (February 2002): 205–11. https://doi.org/10.1016/s1040-8428(01)00157-3.
       Full Text  Link to Item
    • Li, Donghui, Pervez F. Firozi, Weiqing Zhang, Jianjun Shen, John DiGiovanni, Serrine Lau, Douglas Evans, Helmut Friess, Manal Hassan, and James L. Abbruzzese. “DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer.” Mutat Res 513, no. 1–2 (January 15, 2002): 37–48. https://doi.org/10.1016/s1383-5718(01)00291-1.
       Full Text  Link to Item
    • Abbruzzese, J. L. “New applications of gemcitabine and future directions in the management of pancreatic cancer.” Cancer 95, no. 4 SUPPL. (2002): 941–45.
    • Abbruzzese, J. L. “Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality.” Seminars in Oncology 29, no. 6 SUPPL. 20 (2002): 2–8.
    • Lenzi, Renato, Suayib Yalcin, Douglas B. Evans, and James L. Abbruzzese. “Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.” Cancer Invest 20, no. 4 (2002): 464–72. https://doi.org/10.1081/cnv-120002146.
       Full Text  Link to Item
    • Soliman, Amr S., Nabih El-Ghawalby, Farouk Ezzat, Melissa L. Bondy, Ahmed Soultan, Mohamed Abdel-Wahab, Omar Fathy, et al. “Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt.” Int J Gastrointest Cancer 32, no. 2–3 (2002): 143–51. https://doi.org/10.1385/IJGC:32:2-3:143.
       Full Text  Link to Item
    • Xiong, H. Q., and J. L. Abbruzzese. “Epidermal growth factor receptor-targeted therapy for pancreatic cancer.” Seminars in Oncology 29, no. 5 SUPPL. 14 (2002): 31–37.
    • Abbruzzese, J. L. “International Journal of Gastrointestinal Cancer: Letter from the editor.” International Journal of Gastrointestinal Cancer 30, no. 1–2 (December 1, 2001): 1.
    • Reid, T., E. Galanis, J. Abbruzzese, D. Sze, J. Andrews, L. Romel, M. Hatfield, J. Rubin, and D. Kirn. “Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.” Gene Ther 8, no. 21 (November 2001): 1618–26. https://doi.org/10.1038/sj.gt.3301512.
       Full Text  Link to Item
    • Tseng, J. E., B. S. Glisson, F. R. Khuri, D. M. Shin, J. N. Myers, A. K. El-Naggar, J. S. Roach, et al. “Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.” Cancer 92, no. 9 (November 1, 2001): 2364–73. https://doi.org/10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.
       Full Text  Link to Item
    • Kuniyasu, H., J. L. Abbruzzese, K. R. Cleary, and I. J. Fidler. “Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma.” Int J Oncol 19, no. 4 (October 2001): 681–85. https://doi.org/10.3892/ijo.19.4.681.
       Full Text  Link to Item
    • Abbruzzese, J. L., A. M. Lowy, and D. Pleskow. “The latest approaches to pancreatic disease.” Patient Care 35, no. 17 (September 15, 2001): 55–70.
    • Sanfilippo, N. J., C. H. Crane, J. Skibber, B. Feig, J. L. Abbruzzese, S. Curley, J. N. Vauthey, et al. “T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.” Int J Radiat Oncol Biol Phys 51, no. 1 (September 1, 2001): 176–83. https://doi.org/10.1016/s0360-3016(01)01610-8.
       Full Text  Link to Item
    • Hess, K. R., and J. L. Abbruzzese. “Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design.” J Clin Oncol 19, no. 15 (August 1, 2001): 3445–46. https://doi.org/10.1200/JCO.2001.19.15.3445.
       Full Text  Link to Item
    • Wolff, R. A., D. B. Evans, D. M. Gravel, R. Lenzi, P. W. Pisters, J. E. Lee, N. A. Janjan, C. Charnsangavej, and J. L. Abbruzzese. “Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.” Clin Cancer Res 7, no. 8 (August 2001): 2246–53.
       Link to Item
    • Ho, L., U. Aytac, L. C. Stephens, K. Ohnuma, G. B. Mills, K. S. McKee, C. Neumann, et al. “In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.” Clin Cancer Res 7, no. 7 (July 2001): 2031–40.
       Link to Item
    • Shi, Q., X. Le, B. Wang, J. L. Abbruzzese, Q. Xiong, Y. He, and K. Xie. “Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.” Oncogene 20, no. 28 (June 21, 2001): 3751–56. https://doi.org/10.1038/sj.onc.1204500.
       Full Text  Link to Item
    • Crane, C. H., R. A. Wolff, J. L. Abbruzzese, D. B. Evans, L. Milas, K. Mason, C. Charnsangavej, et al. “Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.” Semin Oncol 28, no. 3 Suppl 10 (June 2001): 25–33. https://doi.org/10.1053/sonc.2001.22536.
       Full Text  Link to Item
    • Shi, Q., X. Le, J. L. Abbruzzese, Z. Peng, C. N. Qian, H. Tang, Q. Xiong, B. Wang, X. C. Li, and K. Xie. “Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.” Cancer Res 61, no. 10 (May 15, 2001): 4143–54.
       Link to Item
    • Koul, D., Y. Yao, J. L. Abbruzzese, W. K. Yung, and S. A. Reddy. “Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.” J Biol Chem 276, no. 14 (April 6, 2001): 11402–8. https://doi.org/10.1074/jbc.M007806200.
       Full Text  Link to Item
    • Janjan, N. A., C. Crane, B. W. Feig, K. Cleary, R. Dubrow, S. Curley, J. N. Vauthey, et al. “Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer.” Am J Clin Oncol 24, no. 2 (April 2001): 107–12. https://doi.org/10.1097/00000421-200104000-00001.
       Full Text  Link to Item
    • Breslin, T. M., K. R. Hess, D. B. Harbison, M. E. Jean, K. R. Cleary, A. P. Dackiw, R. A. Wolff, et al. “Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.” Ann Surg Oncol 8, no. 2 (March 2001): 123–32. https://doi.org/10.1007/s10434-001-0123-4.
       Full Text  Link to Item
    • Herbst, R. S., A. T. Lee, H. T. Tran, and J. L. Abbruzzese. “Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.” Curr Oncol Rep 3, no. 2 (March 2001): 131–40. https://doi.org/10.1007/s11912-001-0013-8.
       Full Text  Link to Item
    • Abbruzzese, J. L. “Editor's note.” International Journal of Pancreatology 29, no. 1 (January 1, 2001).
    • Crane, C. H., N. A. Janjan, D. B. Evans, R. A. Wolff, M. T. Ballo, L. Milas, K. Mason, et al. “Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.” International Journal of Pancreatology 29, no. 1 (2001): 9–18.
    • Crane, C. H., R. A. Wolff, J. L. Abbruzzese, D. B. Evans, L. Milas, K. Mason, C. Charnsangavej, et al. “Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index.” Seminars in Oncology 28, no. 3 SUPPL. 10 (2001): 25–33.
    • Wang, B., Q. Xiong, Q. Shi, X. Le, J. L. Abbruzzese, and K. Xie. “Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma.” Cancer Res 61, no. 1 (January 1, 2001): 71–75.
       Link to Item
    • Crane, C. H., N. A. Janjan, D. B. Evans, R. A. Wolff, M. T. Ballo, L. Milas, K. Mason, et al. “Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.” Int J Pancreatol 29, no. 1 (2001): 9–18. https://doi.org/10.1385/IJGC:29:1:09.
       Full Text  Link to Item
    • Crane, C. H., N. A. Janjan, J. L. Abbruzzese, S. Curley, J. Vauthey, H. B. Sawaf, R. Dubrow, et al. “Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.” Int J Radiat Oncol Biol Phys 49, no. 1 (January 1, 2001): 107–16. https://doi.org/10.1016/s0360-3016(00)00777-x.
       Full Text  Link to Item
    • Wang, B., Q. Shi, J. L. Abbruzzese, Q. Xiong, X. Le, and K. Xie. “A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy.” Int J Pancreatol 29, no. 1 (2001): 37–46. https://doi.org/10.1385/IJGC:29:1:37.
       Full Text  Link to Item
    • Xie, K., B. Wang, Q. Shi, J. L. Abbruzzese, Q. Xiong, and X. Le. “Mouse models of metastatic pancreatic adenocarcinoma.” Int J Pancreatol 29, no. 1 (2001): 25–35. https://doi.org/10.1385/IJGC:29:1:25.
       Full Text  Link to Item
    • Hoff, P. M., J. A. Ellerton, S. R. Dakhil, R. J. Winn, J. L. Abbruzzese, and R. Pazdur. “Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.” Am J Clin Oncol 23, no. 6 (December 2000): 602–4. https://doi.org/10.1097/00000421-200012000-00015.
       Full Text  Link to Item
    • Pentz, R. D., M. Z. Cohen, A. Flamm, R. Herbst, J. L. Abbruzzese, and A. M. Woll. “Patients' perceptions of a high-profile phase 1 trial.” Clinical Cancer Research 6 (November 1, 2000): 4575S-4575S.
       Link to Item
    • Le, X., Q. Shi, B. Wang, Q. Xiong, C. Qian, Z. Peng, X. C. Li, H. Tang, J. L. Abbruzzese, and K. Xie. “Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma.” J Interferon Cytokine Res 20, no. 11 (November 2000): 935–46. https://doi.org/10.1089/10799900050198372.
       Full Text  Link to Item
    • Shi, Q., X. Le, B. Wang, Q. Xiong, J. L. Abbruzzese, and K. Xie. “Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells.” J Interferon Cytokine Res 20, no. 11 (November 2000): 1023–28. https://doi.org/10.1089/10799900050198471.
       Full Text  Link to Item
    • Hoff, P. M., N. Janjan, E. D. Saad, J. Skibber, C. Crane, Y. Lassere, K. R. Cleary, et al. “Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.” J Clin Oncol 18, no. 20 (October 15, 2000): 3529–34. https://doi.org/10.1200/JCO.2000.18.20.3529.
       Full Text  Link to Item
    • Pearson, A. S., P. Chiao, L. Zhang, W. Zhang, L. Larry, R. L. Katz, D. B. Evans, and J. L. Abbruzzese. “The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration.” Int J Oncol 17, no. 2 (August 2000): 381–85. https://doi.org/10.3892/ijo.17.2.381.
       Full Text  Link to Item
    • Steinbach, G., P. M. Lynch, R. K. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, N. Wakabayashi, et al. “The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.” N Engl J Med 342, no. 26 (June 29, 2000): 1946–52. https://doi.org/10.1056/NEJM200006293422603.
       Full Text  Link to Item
    • Bruns, C. J., C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, et al. “Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.” Cancer Res 60, no. 11 (June 1, 2000): 2926–35.
       Link to Item
    • Janjan, N. A., C. N. Crane, B. W. Feig, K. Cleary, R. Dubrow, S. A. Curley, L. M. Ellis, et al. “Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.” Int J Radiat Oncol Biol Phys 47, no. 3 (June 1, 2000): 713–18. https://doi.org/10.1016/s0360-3016(00)00418-1.
       Full Text  Link to Item
    • Bruns, C. J., M. T. Harbison, D. W. Davis, C. A. Portera, R. Tsan, D. J. McConkey, D. B. Evans, J. L. Abbruzzese, D. J. Hicklin, and R. Radinsky. “Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.” Clin Cancer Res 6, no. 5 (May 2000): 1936–48.
       Link to Item
    • Madden, T., H. T. Tran, D. Beck, R. Huie, R. A. Newman, L. Pusztai, J. J. Wright, and J. L. Abbruzzese. “Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.” Clin Cancer Res 6, no. 4 (April 2000): 1293–1301.
       Link to Item
    • Pisters, P. W., W. A. Hudec, J. E. Lee, I. Raijman, S. Lahoti, N. A. Janjan, T. A. Rich, et al. “Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.” J Clin Oncol 18, no. 4 (February 2000): 860–67. https://doi.org/10.1200/JCO.2000.18.4.860.
       Full Text  Link to Item
    • Wolff, R. A., P. Chiao, R. Lenzi, P. W. Pisters, J. E. Lee, N. A. Janjan, C. H. Crane, D. B. Evans, and J. L. Abbruzzese. “Current approaches and future strategies for pancreatic carcinoma.” Invest New Drugs 18, no. 1 (February 2000): 43–56. https://doi.org/10.1023/a:1006383831045.
       Full Text  Link to Item
    • Mullani, N. A., R. S. Herbst, J. L. Abbruzzese, B. Barron, L. Lamki, C. Charnsangavej, E. Kim, H. T. Tran, A. Jiwani, and K. L. Gould. “First pass FDG measured blood flow in tumors: A comparison with O-15 labeled water measured blood flow.” Clinical Positron Imaging (Netherlands) 3, no. 4 (January 1, 2000): 153. https://doi.org/10.1016/S1095-0397(00)00065-0.
       Full Text
    • Mullani, N. A., R. S. Herbst, J. L. Abbruzzese, C. Charnsangavej, E. Kim, H. T. Tran, B. Barron, L. Lamki, and K. L. Gould. “Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors.” Clinical Positron Imaging (Netherlands) 3, no. 4 (January 1, 2000): 151. https://doi.org/10.1016/S1095-0397(00)00063-7.
       Full Text
    • Abbruzzese, J. L. “Molecular diagnosis of pancreatic and biliary cancer: ready for broad implementation?” Cancer J 6, no. 5 (2000): 282–84.
       Link to Item
    • Hawes, R. H., Q. Xiong, I. Waxman, K. J. Chang, D. B. Evans, and J. L. Abbruzzese. “A multispecialty approach to the diagnosis and management of pancreatic cancer.” Am J Gastroenterol 95, no. 1 (January 2000): 17–31. https://doi.org/10.1111/j.1572-0241.2000.01699.x.
       Full Text  Link to Item
    • Shi, Q., X. Le, J. L. Abbruzzese, B. Wang, N. Mujaida, K. Matsushima, S. Huang, Q. Xiong, and K. Xie. “Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia.” J Interferon Cytokine Res 19, no. 12 (December 1999): 1363–71. https://doi.org/10.1089/107999099312821.
       Full Text  Link to Item
    • Hess, K. R., M. C. Abbruzzese, R. Lenzi, M. N. Raber, and J. L. Abbruzzese. “Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.” Clin Cancer Res 5, no. 11 (November 1999): 3403–10.
       Link to Item
    • Shi, Q., J. L. Abbruzzese, S. Huang, I. J. Fidler, Q. Xiong, and K. Xie. “Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic.” Clin Cancer Res 5, no. 11 (November 1999): 3711–21.
       Link to Item
    • Wang, W., J. L. Abbruzzese, D. B. Evans, and P. J. Chiao. “Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.” Oncogene 18, no. 32 (August 12, 1999): 4554–63. https://doi.org/10.1038/sj.onc.1202833.
       Full Text  Link to Item
    • Janjan, N. A., V. S. Khoo, J. Abbruzzese, R. Pazdur, R. Dubrow, K. R. Cleary, P. K. Allen, et al. “Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.” Int J Radiat Oncol Biol Phys 44, no. 5 (July 15, 1999): 1027–38. https://doi.org/10.1016/s0360-3016(99)00099-1.
       Full Text  Link to Item
    • Ravandi, F., M. E. Rytting, C. Osmon, E. L. Braud, R. W. Roach, K. Edwards, R. Winn, J. L. Abbruzzese, and R. Pazdur. “Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.” Anticancer Drugs 10, no. 6 (July 1999): 519–24. https://doi.org/10.1097/00001813-199907000-00002.
       Full Text  Link to Item
    • Janjan, N. A., J. Abbruzzese, R. Pazdur, V. S. Khoo, K. Cleary, R. Dubrow, J. Ajani, et al. “Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.” Radiother Oncol 51, no. 2 (May 1999): 153–60. https://doi.org/10.1016/s0167-8140(99)00054-7.
       Full Text  Link to Item
    • Kuniyasu, H., L. M. Ellis, D. B. Evans, J. L. Abbruzzese, C. J. Fenoglio, C. D. Bucana, K. R. Cleary, E. Tahara, and I. J. Fidler. “Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma.” Clin Cancer Res 5, no. 1 (January 1999): 25–33.
       Link to Item
    • Wang, W., J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary, and P. J. Chiao. “The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.” Clin Cancer Res 5, no. 1 (January 1999): 119–27.
       Link to Item
    • Bold, R. J., C. Charnsangavej, K. R. Cleary, M. Jennings, A. Madray, S. D. Leach, J. L. Abbruzzese, P. W. Pisters, J. E. Lee, and D. B. Evans. “Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis.” J Gastrointest Surg 3, no. 3 (1999): 233–43. https://doi.org/10.1016/s1091-255x(99)80065-1.
       Full Text  Link to Item
    • Bold, R. J., K. R. Hess, A. S. Pearson, A. M. Grau, F. A. Sinicrope, M. Jennings, D. J. McConkey, et al. “Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.” J Gastrointest Surg 3, no. 3 (1999): 263–77. https://doi.org/10.1016/s1091-255x(99)80068-7.
       Full Text  Link to Item
    • Evans, D. B., and J. L. Abbruzzese. “Chemoradiation for localized pancreatic cancer: another perspective.” Ann Surg Oncol 6, no. 1 (1999): 4–7. https://doi.org/10.1007/s10434-999-0004-9.
       Full Text  Link to Item
    • Bouvet, M., R. J. Bold, J. Lee, D. B. Evans, J. L. Abbruzzese, P. J. Chiao, D. J. McConkey, et al. “Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments].” Ann Surg Oncol 5, no. 8 (December 1998): 681–88. https://doi.org/10.1007/BF02303477.
       Full Text  Link to Item
    • Melichar, B., G. Ferrandina, C. F. Verschraegen, A. Loercher, J. L. Abbruzzese, and R. S. Freedman. “Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.” Clin Cancer Res 4, no. 12 (December 1998): 3069–76.
       Link to Item
    • Raijman, I., I. Siddique, J. Ajani, D. Evans, J. Abbruzzese, S. Lahoti, and P. Lynch. “Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents.” Gastrointestinal Endoscopy 47, no. 4 (December 1, 1998).
    • Lee, J. E., D. B. Evans, R. C. Hickey, S. I. Sherman, R. F. Gagel, M. C. Abbruzzese, and J. L. Abbruzzese. “Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas.” Surgery 124, no. 6 (December 1998): 1115–22. https://doi.org/10.1067/msy.1998.92009.
       Full Text  Link to Item
    • Pisters, P. W., J. L. Abbruzzese, N. A. Janjan, K. R. Cleary, C. Charnsangavej, M. S. Goswitz, T. A. Rich, et al. “Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.” J Clin Oncol 16, no. 12 (December 1998): 3843–50. https://doi.org/10.1200/JCO.1998.16.12.3843.
       Full Text  Link to Item
    • Touroutoglou, N., D. Gravel, M. N. Raber, W. Plunkett, and J. L. Abbruzzese. “Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.” Ann Oncol 9, no. 9 (September 1998): 1003–8. https://doi.org/10.1023/A:1008487932384.
       Full Text  Link to Item
    • Robinson, E. K., A. M. Grau, D. B. Evans, C. M. Smid, P. J. Chiao, J. L. Abbruzzese, and E. A. Grimm. “Cell cycle regulation of human pancreatic cancer by tamoxifen.” Ann Surg Oncol 5, no. 4 (June 1998): 342–49. https://doi.org/10.1007/BF02303498.
       Full Text  Link to Item
    • Ayoub, J. P., K. R. Hess, M. C. Abbruzzese, R. Lenzi, M. N. Raber, and J. L. Abbruzzese. “Unknown primary tumors metastatic to liver.” J Clin Oncol 16, no. 6 (June 1998): 2105–12. https://doi.org/10.1200/JCO.1998.16.6.2105.
       Full Text  Link to Item
    • Lenzi, R., E. E. Kim, M. N. Raber, and J. L. Abbruzzese. “Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.” Ann Oncol 9, no. 2 (February 1998): 213–16. https://doi.org/10.1023/a:1008265113591.
       Full Text  Link to Item
    • Breslin, T. M., N. A. Janjan, J. E. Lee, P. W. Pisters, R. A. Wolff, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” Frontiers in Bioscience : A Journal and Virtual Library 3 (1998): E193–203.
    • Ettinger, D. S., J. L. Abbruzzese, R. A. Gams, C. D. Jacobs, M. S. Kies, J. Orner, D. Raben, et al. “NCCN practice guidelines for occult primary tumors.” Oncology 12, no. 11 A (1998): 226–309.
    • Wang, M., J. L. Abbruzzese, H. Friess, W. N. Hittelman, D. B. Evans, M. C. Abbruzzese, P. Chiao, and D. Li. “DNA adducts in human pancreatic tissues and their potential role in carcinogenesis.” Cancer Res 58, no. 1 (January 1, 1998): 38–41.
       Link to Item
    • Evans, D. B., P. W. Pisters, J. E. Lee, R. J. Bold, C. Charnsangavej, N. A. Janjan, R. A. Wolff, and J. L. Abbruzzese. “Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.” J Hepatobiliary Pancreat Surg 5, no. 3 (1998): 242–50. https://doi.org/10.1007/s005340050041.
       Full Text  Link to Item
    • Garteiz, D. A., T. Madden, D. E. Beck, W. R. Huie, K. T. McManus, J. L. Abbruzzese, W. Chen, and R. A. Newman. “Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial.” Cancer Chemother Pharmacol 41, no. 4 (1998): 299–306. https://doi.org/10.1007/s002800050743.
       Full Text  Link to Item
    • Miller, A. R., E. K. Robinson, J. E. Lee, P. W. Pisters, P. J. Chiao, R. L. Lenzi, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” Surg Oncol Clin N Am 7, no. 1 (January 1998): 183–97.
       Link to Item
    • Miller, A. R., P. W. Pisters, J. E. Lee, N. A. Janjan, J. L. Abbruzzese, and D. B. Evans. “Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.” Hepatogastroenterology 45, no. 21 (1998): 624–33.
       Link to Item
    • Pazdur, R., D. C. Medgyesy, R. J. Winn, S. R. Dakhil, D. F. Moore, A. Scalzo, P. M. Hoff, S. G. Arbuck, and J. L. Abbruzzese. “Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.” Invest New Drugs 16, no. 4 (1998): 341–46. https://doi.org/10.1023/a:1006248700232.
       Full Text  Link to Item
    • Abbruzzese, J. L. “The Michael/Moore Article Reviewed.” Oncology 11, no. 11 (December 1, 1997): 1622–25.
    • Mason, K. A., N. R. Hunter, M. Milas, J. L. Abbruzzese, and L. Milas. “Docetaxel enhances tumor radioresponse in vivo.” Clin Cancer Res 3, no. 12 Pt 1 (December 1997): 2431–38.
       Link to Item
    • Pazdur, R., C. Meyers, E. Diaz-Canton, J. L. Abbruzzese, Y. Patt, W. Grove, and J. Ajani. “Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.” Am J Clin Oncol 20, no. 6 (December 1997): 573–76. https://doi.org/10.1097/00000421-199712000-00008.
       Full Text  Link to Item
    • “NCCN practice guidelines for pancreatic cancer.” Oncology (Williston Park) 11, no. 11A (November 1997): 41–55.
       Link to Item
    • Ferrandina, G., B. Melichar, A. Loercher, C. F. Verschraegen, A. P. Kudelka, C. L. Edwards, G. Scambia, J. J. Kavanagh, J. L. Abbruzzese, and R. S. Freedman. “Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.” Cancer Res 57, no. 19 (October 1, 1997): 4309–15.
       Link to Item
    • Grau, A. M., L. Zhang, W. Wang, S. Ruan, D. B. Evans, J. L. Abbruzzese, W. Zhang, and P. J. Chiao. “Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.” Cancer Res 57, no. 18 (September 15, 1997): 3929–34.
       Link to Item
    • Pazdur, R., E. Diaz-Canton, W. P. Ballard, J. E. Bradof, S. Graham, S. G. Arbuck, J. L. Abbruzzese, and R. Winn. “Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.” J Clin Oncol 15, no. 8 (August 1997): 2905–9. https://doi.org/10.1200/JCO.1997.15.8.2905.
       Full Text  Link to Item
    • Lenzi, R., K. R. Hess, M. C. Abbruzzese, M. N. Raber, N. G. Ordoñez, and J. L. Abbruzzese. “Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?” J Clin Oncol 15, no. 5 (May 1997): 2056–66. https://doi.org/10.1200/JCO.1997.15.5.2056.
       Full Text  Link to Item
    • Spitz, F. R., J. L. Abbruzzese, J. E. Lee, P. W. Pisters, A. M. Lowy, C. J. Fenoglio, K. R. Cleary, et al. “Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.” J Clin Oncol 15, no. 3 (March 1997): 928–37. https://doi.org/10.1200/JCO.1997.15.3.928.
       Full Text  Link to Item
    • Abbruzzese, J. L., D. B. Evans, I. Raijman, L. Larry, T. King, S. D. Leach, and M. L. Frazier. “Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.” Anticancer Research 17, no. 2 A (1997): 795–801.
    • Evans, D. B., J. E. Lee, P. W. Pisters, C. Charnsangavej, L. M. Ellis, P. J. Chiao, R. Lenzi, and J. L. Abbruzzese. “Advances in the diagnosis and treatment of adenocarcinoma of the pancreas.” Cancer Treat Res 90 (1997): 109–25. https://doi.org/10.1007/978-1-4615-6165-1_6.
       Full Text  Link to Item
    • Mason, K. A., N. R. Hunter, M. Milas, J. L. Abbruzzese, and L. Milas. “Docetaxel enhances tumor radioresponse in vivo.” Clinical Cancer Research 3, no. 12 I (1997): 2431–38.
    • Raijman, I., I. Siddique, P. Lynch, Y. Patt, M. Roh, S. Curley, J. Lee, P. Pisters, D. Evans, and J. Abbruzzese. “Endoscopic management of biliary tract cancer with the wallstent: Experience in 121 patients.” Gastrointestinal Endoscopy 45, no. 4 (January 1, 1997). https://doi.org/10.1016/S0016-5107(97)80483-X.
       Full Text
    • Raijman, I., I. Siddique, P. Lynch, Y. Patt, M. Roh, S. Curley, J. Lee, P. Pisters, D. Evans, and J. Abbruzzese. “Comparison between metastatic vs primary biliary tract cancer in their response to the wallstent.” Gastrointestinal Endoscopy 45, no. 4 (January 1, 1997). https://doi.org/10.1016/S0016-5107(97)80482-8.
       Full Text
    • Abbruzzese, J. L., D. B. Evans, I. Raijman, L. Larry, T. King, S. D. Leach, and M. L. Frazier. “Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.” Anticancer Res 17, no. 2A (1997): 795–801.
       Link to Item
    • Evans, D. B., C. A. Staley, J. E. Lee, P. W. T. Pisters, and J. L. Abbruzzese. “Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies.” Gi Cancer 1, no. 3 (December 1, 1996): 149–61.
    • Sinicrope, F. A., D. B. Evans, S. D. Leach, K. R. Cleary, C. J. Fenoglio, J. J. Lee, and J. L. Abbruzzese. “bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.” Clin Cancer Res 2, no. 12 (December 1996): 2015–22.
       Link to Item
    • Beran, M., H. Kantarjian, S. O’Brien, C. Koller, M. al-Bitar, S. Arbuck, S. Pierce, et al. “Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.” Blood 88, no. 7 (October 1, 1996): 2473–79.
       Link to Item
    • Abbruzzese, J. L. “Phase I studies with the novel nucleoside analog gemcitabine.” Semin Oncol 23, no. 5 Suppl 10 (October 1996): 25–31.
       Link to Item
    • Abbruzzese, J. L., T. Madden, S. M. Sugarman, A. L. Ellis, S. Loughlin, K. R. Hess, R. A. Newman, L. A. Zwelling, and M. N. Raber. “Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.” Clin Cancer Res 2, no. 9 (September 1996): 1489–97.
       Link to Item
    • Rothenberg, M. L., J. L. Abbruzzese, M. Moore, R. K. Portenoy, J. M. Robertson, and H. J. Wanebo. “A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.” Cancer 78, no. 3 Suppl (August 1, 1996): 627–32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y.
       Full Text  Link to Item
    • Staley, C. A., K. R. Cleary, J. L. Abbruzzese, J. E. Lee, F. C. Ames, C. J. Fenoglio, and D. B. Evans. “The need for standardized pathologic staging of pancreaticoduodenectomy specimens.” Pancreas 12, no. 4 (May 1996): 373–80. https://doi.org/10.1097/00006676-199605000-00009.
       Full Text  Link to Item
    • Abbruzzese, J. L., M. C. Abbruzzese, R. Lenzi, M. N. Raber, and K. R. Hess. “Are time or intensity factors important to the definition of metastases of unknown origin?” J Natl Cancer Inst 88, no. 7 (April 3, 1996): 462–63. https://doi.org/10.1093/jnci/88.7.462-a.
       Full Text  Link to Item
    • Frazier, M. L., E. Fernández, R. de Llorens, N. M. Brown, S. Pathak, K. R. Cleary, J. L. Abbruzzese, et al. “Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells.” Int J Pancreatol 19, no. 1 (February 1996): 31–38. https://doi.org/10.1007/BF02788373.
       Full Text  Link to Item
    • Abbruzzese, J. L. “Phase I studies with the novel nucleoside analog gemcitabine.” Seminars in Oncology 23, no. 5 SUPPL. 10 (1996): 25–31.
    • Pazdur, R., N. J. Meropol, E. S. Casper, C. Fuchs, H. O. Douglass, M. Vincent, and J. L. Abbruzzese. “Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.” Invest New Drugs 13, no. 4 (1996): 355–58. https://doi.org/10.1007/BF00873144.
       Full Text  Link to Item
    • Staley, C. A., J. E. Lee, K. R. Cleary, J. L. Abbruzzese, C. J. Fenoglio, T. A. Rich, and D. B. Evans. “Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.” Am J Surg 171, no. 1 (January 1996): 118–24. https://doi.org/10.1016/S0002-9610(99)80085-3.
       Full Text  Link to Item
    • Moore, D. F., R. Pazdur, S. Sugarman, D. Jones, S. M. Lippman, B. Bready, and J. L. Abbruzzese. “Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.” Am J Clin Oncol 18, no. 6 (December 1995): 525–27. https://doi.org/10.1097/00000421-199512000-00013.
       Full Text  Link to Item
    • Jones, D. V., R. J. Winn, B. W. Brown, L. B. Levy, R. P. Pugh, J. L. Wade, H. M. Gross, K. B. Pendergrass, B. Levin, and J. L. Abbruzzese. “Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.” Cancer 76, no. 10 (November 15, 1995): 1709–14. https://doi.org/10.1002/1097-0142(19951115)76:10<1709::aid-cncr2820761006>3.0.co;2-5.
       Full Text  Link to Item
    • Evans, D. B., J. L. Abbruzzese, K. R. Cleary, D. J. Buchholz, C. J. Fenoglio, C. Collier, and T. A. Rich. “Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.” Int J Radiat Oncol Biol Phys 33, no. 4 (November 1, 1995): 913–18. https://doi.org/10.1016/0360-3016(94)00615-2.
       Full Text  Link to Item
    • Evans, O. B., J. L. Abbruzzese, K. R. Cleary, J. E. Lee, D. J. Buchholz, and T. A. Rich. “Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.” J R Coll Surg Edinb 40, no. 5 (October 1995): 319–23.
       Link to Item
    • Pazdur, R., B. Bready, J. A. Ajani, J. L. Abbruzzese, A. Markowitz, S. Sugarman, D. Jones, and B. Levin. “Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.” Am J Clin Oncol 18, no. 5 (October 1995): 436–38. https://doi.org/10.1097/00000421-199510000-00015.
       Full Text  Link to Item
    • Leach, S. D., J. A. Rose, A. M. Lowy, J. E. Lee, C. Charnsangavej, J. L. Abbruzzese, R. L. Katz, and D. B. Evans. “Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head.” Surgery 118, no. 3 (September 1995): 472–78. https://doi.org/10.1016/s0039-6060(05)80361-7.
       Full Text  Link to Item
    • Abbruzzese, J. L., M. C. Abbruzzese, R. Lenzi, K. R. Hess, and M. N. Raber. “Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.” J Clin Oncol 13, no. 8 (August 1995): 2094–2103. https://doi.org/10.1200/JCO.1995.13.8.2094.
       Full Text  Link to Item
    • Evans, D. B., J. L. Abbruzzese, J. E. Lee, S. D. Leach, C. Charnsangavej, K. R. Cleary, D. J. Buchholz, and T. A. Rich. “Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience.” Seminars in Surgical Oncology 11, no. 2 (January 1, 1995): 132–40. https://doi.org/10.1002/ssu.2980110210.
       Full Text
    • Jones, D. V., K. R. Daugherty, and J. L. Abbruzzese. “A phase I clinical trial of a protracted continuous infusion of 5-fluorouracil with oral folinic acid in patients with unresectable adenocarcinoma of the colon or rectum.” International Journal of Oncology 7, no. 1 (January 1, 1995): 191–94. https://doi.org/10.3892/ijo.7.1.191.
       Full Text
    • Jones, D. V., S. M. Sugarman, A. B. Markowitz, B. Levin, J. L. Abbruzzese, D. B. Evans, C. Charnsangavej, R. Smith, and Y. Z. Patt. “Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas.” Oncology Reports 2, no. 6 (January 1, 1995): 1121–23. https://doi.org/10.3892/or.2.6.1121.
       Full Text
    • Lenzi, R., M. N. Raber, D. Gravel, P. Frost, and J. L. Abbruzzese. “Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine.” International Journal of Oncology 6, no. 2 (January 1, 1995): 447–50.
    • Lenzi, R., M. N. Raber, S. B. Schmidt, and J. L. Abbruzzese. “A pilot study of paclitaxel in previously treated patients with metastatic unknown primary carcinomas.” Oncology Reports 2, no. 6 (January 1, 1995): 1127–28. https://doi.org/10.3892/or.2.6.1127.
       Full Text
    • Abbruzzese, J. L. “Novel diagnostic and therapeutic approaches to pancreatic cancer.” Cancer Bulletin 46, no. 6 (December 1, 1994): 525–31.
    • Leach, S. D., T. A. Rich, J. L. Abbruzzese, J. E. Lee, K. R. Cleary, R. L. Katz, C. Charnsangavej, et al. “Preoperative chemoradiotherapy, pancreaticoduodenectomy, and external- beam intraoperative radiotherapy for pancreatic adenocarcinoma: The M.D. Anderson experience.” Cancer Bulletin 46, no. 6 (December 1, 1994): 518–24.
    • Pazdur, R., Y. Lassere, V. Rhodes, J. A. Ajani, S. M. Sugarman, Y. Z. Patt, D. V. Jones, A. B. Markowitz, J. L. Abbruzzese, and B. Bready. “Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.” J Clin Oncol 12, no. 11 (November 1994): 2296–2300. https://doi.org/10.1200/JCO.1994.12.11.2296.
       Full Text  Link to Item
    • Abbruzzese, J. L., M. C. Abbruzzese, K. R. Hess, M. N. Raber, R. Lenzi, and P. Frost. “Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.” J Clin Oncol 12, no. 6 (June 1994): 1272–80. https://doi.org/10.1200/JCO.1994.12.6.1272.
       Full Text  Link to Item
    • Pazdur, R., Y. Lassere, L. T. Soh, J. A. Ajani, B. Bready, E. Soo, S. Sugarman, Y. Patt, J. L. Abbruzzese, and B. Levin. “Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.” Ann Oncol 5, no. 5 (May 1994): 468–70. https://doi.org/10.1093/oxfordjournals.annonc.a058883.
       Full Text  Link to Item
    • Hubbard, K. P., J. O. Roehm, and J. L. Abbruzzese. “The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies.” Am J Clin Oncol 17, no. 2 (April 1994): 115–17.
       Link to Item
    • Moore, D. F., R. Pazdur, J. L. Abbruzzese, J. A. Ajani, D. W. Dubovsky, J. L. Wade, R. J. Belt, C. Mangold, B. Bready, and R. J. Winn. “Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.” Ann Oncol 5, no. 3 (March 1994): 286–87. https://doi.org/10.1093/oxfordjournals.annonc.a058810.
       Full Text  Link to Item
    • Moore, D. F., R. Pazdur, and J. L. Abbruzzese. “Phase II trial of intravenous melphalan in advanced colorectal carcinoma.” Invest New Drugs 12, no. 2 (1994): 133–36. https://doi.org/10.1007/BF00874443.
       Full Text  Link to Item
    • Fuhrman, G. M., C. Charnsangavej, J. L. Abbruzzese, K. R. Cleary, R. G. Martin, C. J. Fenoglio, and D. B. Evans. “Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.” Am J Surg 167, no. 1 (January 1994): 104–11. https://doi.org/10.1016/0002-9610(94)90060-4.
       Full Text  Link to Item
    • Lenzi, R., P. Frost, and J. L. Abbruzzese. “Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.” Anticancer Res 14, no. 1A (1994): 247–51.
       Link to Item
    • Lenzi, R., P. Frost, and J. L. Abbruzzese. “Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.” Anticancer Research 14, no. 1 A (1994): 247–51.
    • Jones, D. V., Y. Z. Patt, J. A. Ajani, J. Abbruzzese, C. H. Carrasco, C. Charnsangavej, B. Levin, and S. Wallace. “A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.” Cancer 72, no. 9 (November 1, 1993): 2560–63. https://doi.org/10.1002/1097-0142(19931101)72:9<2560::aid-cncr2820720908>3.0.co;2-e.
       Full Text  Link to Item
    • Lee-Jackson, D., J. L. Abbruzzese, and M. Bar-Eli. “Artifactual frame-shift p53 mutation at codon 249 detected with the Cyclist DNA sequencing method.” Biotechniques 15, no. 3 (September 1993): 363–64.
       Link to Item
    • Abbruzzese, J. L., R. Lenzi, M. N. Raber, S. Pathak, and P. Frost. “The biology of unknown primary tumors.” Semin Oncol 20, no. 3 (June 1993): 238–43.
       Link to Item
    • Ajani, J. A., J. L. Abbruzzese, A. B. Markowitz, Y. Z. Patt, and K. Daugherty. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.” Invest New Drugs 11, no. 1 (February 1993): 67–69. https://doi.org/10.1007/BF00873914.
       Full Text  Link to Item
    • Ellerhorst, J. A., P. Frost, J. L. Abbruzzese, R. A. Newman, and Y. Chernajovsky. “2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.” Br J Cancer 67, no. 2 (February 1993): 209–15. https://doi.org/10.1038/bjc.1993.41.
       Full Text  Link to Item
    • Lenzi, R., M. N. Raber, P. Frost, S. Schmidt, and J. L. Abbruzzese. “Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.” Eur J Cancer 29A, no. 11 (1993): 1634. https://doi.org/10.1016/0959-8049(93)90312-4.
       Full Text  Link to Item
    • Bar-Eli, M., J. L. Abbruzzese, D. Lee-Jackson, and P. Frost. “p53 gene mutation spectrum in human unknown primary tumors.” Anticancer Res 13, no. 5A (1993): 1619–23.
       Link to Item
    • Bar-Eli, M., J. L. Abbruzzese, D. Lee-Jackson, and P. Frost. “p53 Gene mutation spectrum in human unknown primary tumors.” Anticancer Research 13, no. 5 A (1993): 1619–23.
    • Hubbard, K. P., R. Pazdur, J. A. Ajani, E. Braud, A. Blaustein, M. King, M. Llenado-Lee, R. Winn, B. Levin, and J. L. Abbruzzese. “Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.” Am J Clin Oncol 15, no. 6 (December 1992): 524–27.
       Link to Item
    • Moore, D. F., R. Pazdur, K. Daugherty, P. Tarassoff, and J. L. Abbruzzese. “Phase II study of gemcitabine in advanced colorectal adenocarcinoma.” Invest New Drugs 10, no. 4 (November 1992): 323–25. https://doi.org/10.1007/BF00944189.
       Full Text  Link to Item
    • Pazdur, R., J. J. Ajani, J. L. Abbruzzese, R. J. Belt, S. R. Dakhil, D. Dubovsky, S. Graham, S. Pilat, R. Winn, and B. Levin. “Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.” Cancer 70, no. 8 (October 15, 1992): 2073–76. https://doi.org/10.1002/1097-0142(19921015)70:8<2073::aid-cncr2820700810>3.0.co;2-a.
       Full Text  Link to Item
    • Jones, D. V., J. A. Ajani, R. Blackburn, K. Daugherty, B. Levin, Y. Z. Patt, and J. L. Abbruzzese. “Phase II study of didemnin B in advanced colorectal cancer.” Invest New Drugs 10, no. 3 (August 1992): 211–13. https://doi.org/10.1007/BF00877248.
       Full Text  Link to Item
    • Anzai, H., P. Frost, and J. L. Abbruzzese. “Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.” Cancer Res 52, no. 8 (April 15, 1992): 2180–85.
       Link to Item
    • Hubbard, K. P., K. Daugherty, J. A. Ajani, R. Pazdur, B. Levin, and J. L. Abbruzzese. “Phase II trial of fazarabine in advanced colorectal carcinoma.” Invest New Drugs 10, no. 1 (April 1992): 39–42. https://doi.org/10.1007/BF01275479.
       Full Text  Link to Item
    • Raber, M. N., J. L. Abbruzzese, and P. Frost. “Unknown primary tumors.” Curr Opin Oncol 4, no. 1 (February 1992): 3–9.
       Link to Item
    • Meyers, C. A., and J. L. Abbruzzese. “Cognitive functioning in cancer patients: effect of previous treatment.” Neurology 42, no. 2 (February 1992): 434–36. https://doi.org/10.1212/wnl.42.2.434.
       Full Text  Link to Item
    • Abbruzzese, J. L., C. F. Gholson, K. Daugherty, E. Larson, R. DuBrow, R. Berlin, and B. Levin. “A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.” Pancreas 7, no. 2 (1992): 165–71. https://doi.org/10.1097/00006676-199203000-00006.
       Full Text  Link to Item
    • Abbruzzese, J. L., and P. Frost. “Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.” Cancer Chemother Pharmacol 30, no. 1 (1992): 31–36. https://doi.org/10.1007/BF00686482.
       Full Text  Link to Item
    • Abbruzzese, J. L., and P. P. Carbone. “Adenocarcinoma of the liver without a detectable primary.” Hosp Pract (Off Ed) 26, no. 12 (December 15, 1991): 61-passim. https://doi.org/10.1080/21548331.1991.11704236.
       Full Text  Link to Item
    • Ajani, J. A., R. Pazdur, R. J. Winn, J. L. Abbruzzese, B. Levin, R. Belt, J. Young, Y. Z. Patt, and I. H. Krakoff. “Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.” Invest New Drugs 9, no. 4 (November 1991): 369–71. https://doi.org/10.1007/BF00183584.
       Full Text  Link to Item
    • Linke, K., R. Pazdur, J. L. Abbruzzese, J. A. Ajani, R. Winn, J. E. Bradof, K. Daugherty, and B. Levin. “Phase II study of amonafide in advanced pancreatic adenocarcinoma.” Invest New Drugs 9, no. 4 (November 1991): 353–56. https://doi.org/10.1007/BF00183580.
       Full Text  Link to Item
    • Lee, N. K., R. M. Byers, J. L. Abbruzzese, and P. Wolf. “Metastatic adenocarcinoma to the neck from an unknown primary source.” Am J Surg 162, no. 4 (October 1991): 306–9. https://doi.org/10.1016/0002-9610(91)90137-3.
       Full Text  Link to Item
    • Ajani, J. A., R. Pazdur, R. J. Winn, J. L. Abbruzzese, B. Levin, C. Wiseman, M. A. Lenado-Lee, Y. Z. Patt, and I. H. Krakoff. “Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.” Invest New Drugs 9, no. 3 (August 1991): 257–59. https://doi.org/10.1007/BF00176979.
       Full Text  Link to Item
    • Raber, M. N., J. Faintuch, J. L. Abbruzzese, C. Sumrall, and P. Frost. “Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.” Ann Oncol 2, no. 7 (July 1991): 519–20. https://doi.org/10.1093/oxfordjournals.annonc.a058007.
       Full Text  Link to Item
    • Abbruzzese, J. L., R. Grunewald, E. A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, and M. N. Raber. “A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.” J Clin Oncol 9, no. 3 (March 1991): 491–98. https://doi.org/10.1200/JCO.1991.9.3.491.
       Full Text  Link to Item
    • Grunewald, R., J. L. Abbruzzese, P. Tarassoff, and W. Plunkett. “Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.” Cancer Chemother Pharmacol 27, no. 4 (1991): 258–62. https://doi.org/10.1007/BF00685109.
       Full Text  Link to Item
    • Pazdur, R., J. A. Ajani, Y. Z. Patt, R. Winn, D. Jackson, B. Shepard, R. DuBrow, L. Campos, M. Quaraishi, and J. Faintuch. “Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.” J Clin Oncol 8, no. 12 (December 1990): 2027–31. https://doi.org/10.1200/JCO.1990.8.12.2027.
       Full Text  Link to Item
    • Grunewald, R., H. Kantarjian, M. J. Keating, J. Abbruzzese, P. Tarassoff, and W. Plunkett. “Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.” Cancer Res 50, no. 21 (November 1, 1990): 6823–26.
       Link to Item
    • Abbruzzese, J. L., B. Levin, J. A. Ajani, J. S. Faintuch, R. Pazdur, S. Saks, C. Edwards, and J. U. Gutterman. “A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.” J Biol Response Mod 9, no. 5 (October 1990): 522–27.
       Link to Item
    • Frost, P., J. L. Abbruzzese, B. Hunt, D. Lee, and M. Ellis. “Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.” Cancer Res 50, no. 15 (August 1, 1990): 4572–77.
       Link to Item
    • Ajani, J. A., J. A. Roth, B. Ryan, M. McMurtrey, T. A. Rich, D. E. Jackson, J. L. Abbruzzese, B. Levin, L. DeCaro, and C. Mountain. “Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.” J Clin Oncol 8, no. 7 (July 1990): 1231–38. https://doi.org/10.1200/JCO.1990.8.7.1231.
       Full Text  Link to Item
    • Abbruzzese, J. L., R. Amato, S. Schmidt, M. N. Raber, and P. Frost. “Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.” Cancer Chemother Pharmacol 26, no. 3 (1990): 159–62. https://doi.org/10.1007/BF02897192.
       Full Text  Link to Item
    • Ajani, J. A., D. M. Ota, V. B. Grossie, J. L. Abbruzzese, J. S. Faintuch, Y. Z. Patt, D. E. Jackson, B. Levin, and K. Nishioka. “Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.” Cancer Chemother Pharmacol 26, no. 3 (1990): 223–26. https://doi.org/10.1007/BF02897204.
       Full Text  Link to Item
    • Ajani, J. A., J. L. Abbruzzese, J. S. Faintuch, Y. Z. Patt, B. M. Boman, D. E. Jackson, B. Levin, and I. H. Krakoff. “A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.” Cancer Invest 8, no. 6 (1990): 619–21. https://doi.org/10.3109/07357909009018929.
       Full Text  Link to Item
    • Abbruzzese, J. L., A. Weeks, M. N. Raber, D. Gravel, R. A. DuBrow, B. Levin, J. Grem, and H. G. Chun. “Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.” J Natl Cancer Inst 81, no. 23 (December 6, 1989): 1840–42. https://doi.org/10.1093/jnci/81.23.1840.
       Full Text  Link to Item
    • Weeks, A. E., J. L. Abbruzzese, and B. Levin. “Current status of chemotherapy for colorectal cancer.” Drug Therapy 19, no. 6 (December 1, 1989): 36–55.
    • Abbruzzese, J. L., B. Levin, J. A. Ajani, J. S. Faintuch, S. Saks, Y. Z. Patt, C. Edwards, K. Ende, and J. U. Gutterman. “Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.” Cancer Res 49, no. 14 (July 15, 1989): 4057–61.
       Link to Item
    • Abbruzzese, J. L., S. Schmidt, M. N. Raber, J. K. Levy, A. M. Castellanos, S. S. Legha, and I. H. Krakoff. “Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.” Invest New Drugs 7, no. 2–3 (July 1989): 195–201. https://doi.org/10.1007/BF00170857.
       Full Text  Link to Item
    • Ajani, J. A., A. A. Rios, K. Ende, J. L. Abbruzzese, C. Edwards, J. S. Faintuch, S. Saks, J. U. Gutterman, and B. Levin. “Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.” J Biol Response Mod 8, no. 2 (April 1989): 140–46.
       Link to Item
    • Abbruzzese, J. L., and B. Levin. “Treatment of advanced colorectal cancer.” Hematol Oncol Clin North Am 3, no. 1 (March 1989): 135–53.
       Link to Item
    • Rich, T. A., L. L. Hughes, J. M. Jessup, D. M. Ota, F. C. Ames, D. C. Hohn, R. G. Martin, J. A. Ajani, and J. L. Abbruzzese. “Conservative management of anal and low rectal cancers with combined modality therapy.” Cancer Bulletin 41, no. 2 (January 1, 1989): 71–74.
    • Ajani, J. A., P. Goudeau, B. Levin, J. S. Faintuch, J. L. Abbruzzese, B. M. Boman, and M. D. Kanojia. “Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.” Cancer Chemother Pharmacol 24, no. 1 (1989): 41–44. https://doi.org/10.1007/BF00254103.
       Full Text  Link to Item
    • Ajani, J. A., J. L. Abbruzzese, P. Goudeau, J. S. Faintuch, A. C. Yeomans, B. M. Boman, C. Nicaise, and B. Levin. “Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.” J Clin Oncol 6, no. 11 (November 1988): 1703–7. https://doi.org/10.1200/JCO.1988.6.11.1703.
       Full Text  Link to Item
    • Ajani, J. A., J. L. Abbruzzese, J. S. Faintuch, R. Blackburn, B. Levin, and B. M. Boman. “Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.” Invest New Drugs 6, no. 1 (April 1988): 47–50. https://doi.org/10.1007/BF00170780.
       Full Text  Link to Item
    • Abbruzzese, J. L. “Recent approaches to the systemic therapy of advanced colorectal carcinoma.” Cancer Bulletin 40, no. 4 (January 1, 1988): 238–43.
    • Levitan, N., W. K. Hong, R. E. Byrne, M. E. Gale, R. H. Bromer, H. L. Levine, J. T. Licciardello, and J. L. Abbruzzese. “Role of computerized cranial tomography in the staging of small cell carcinoma of the lung.” Cancer Treat Rep 68, no. 11 (November 1984): 1375–77.
       Link to Item
    • Abbruzzese, J. L., L. E. Rocco, O. L. Laskin, K. M. Skubitz, M. D. McGaughey, and J. J. Lipsky. “Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections.” Am J Med 74, no. 4 (April 1983): 694–99. https://doi.org/10.1016/0002-9343(83)91029-x.
       Full Text  Link to Item
    • Abbruzzese, J. L., and J. W. Griffin. “Postural hypotension.” Johns Hopkins Med J 148, no. 3 (March 1981): 127–31.
       Link to Item
    • Elder, J. W., J. Abbruzzese, J. Murray, and M. Zielski. “Separation of paprika pigments: An introductory t/c experiment.” Journal of Chemical Education 53 (January 1, 1976): 43. https://doi.org/10.1021/ed053p43.
       Full Text
    • Schoenfeld, Jonathan D., Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z. Kao, Ana Lako, Junko Tsuji, Yang Liu, et al. “Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial,” n.d.

  • Book Sections

    • Varadhachary, G., and J. L. Abbruzzese. “Carcinoma of Unknown Primary.” In Abeloff’s Clinical Oncology, 1694–1702, 2019. https://doi.org/10.1016/B978-0-323-47674-4.00091-8.
       Full Text
    • Choe, J. H., and J. L. Abbruzzese. “Emerging therapeutic targets in pancreatic adenocarcinoma.” In Pancreatic Cancer, 1613–41, 2018. https://doi.org/10.1007/978-1-4939-7193-0_92.
       Full Text
    • Fogelman, D., M. Javle, and J. Abbruzzese. “Molecular Therapeutics: Pancreatic Cancer.” In Targeted Therapy in Translational Cancer Research, 255–62, 2015. https://doi.org/10.1002/9781118468678.ch26.
       Full Text
    • Shroff, R. T., and J. L. Abbruzzese. “Molecular Pathogenesis of Pancreatic Adenocarcinoma.” In The Molecular Basis of Cancer: Fourth Edition, 2015. https://doi.org/10.1016/B978-1-4557-4066-6.00035-4.
       Full Text
    • Varadhachary, G. R., R. Lenzi, M. N. Raber, and J. L. Abbruzzese. “Carcinoma of Unknown Primary.” In Abeloff’s Clinical Oncology: Fifth Edition, 1792-1803.e2, 2014. https://doi.org/10.1016/B978-1-4557-2865-7.00094-1.
       Full Text
    • Varadhachary, G. R., and J. L. Abbruzzese. “Resected pancreatic cancer.” In Diseases of the Pancreas: Current Surgical Therapy, 675–87, 2008. https://doi.org/10.1007/978-3-540-28656-1_65.
       Full Text
    • Xiong, H. Q., and J. L. Abbruzzese. “Molecular pathogenesis of pancreatic adenocarcinoma.” In The Molecular Basis of Cancer, 455–61, 2008. https://doi.org/10.1016/B978-141603703-3.10035-4.
       Full Text
    • Davis, D. W., R. S. Herbst, and J. M. Abbruzzese. “Antiangiogenic cancer therapy,” 1–859, 2007. https://doi.org/10.1201/9781420004298.
       Full Text

  • Conference Papers

    • Calero, M Villalona, A. Patnaik, R. Maki, B. O’Neil, J. Abbruzzese, I. Dagogo-Jack, S. Devarakonda, et al. “Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors.” In Journal of Thoracic Oncology, 17:S457–S457, 2022.
       Link to Item
    • Pandya, Karan, Joanne Xiu, Alex Farrell, Michael J. Overman, Andreas Seeber, Jim Abraham, Anthony Frank Shields, et al. “Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.” In Journal of Clinical Oncology, Vol. 40, 2022.
       Link to Item
    • Villalona-Calero, Miguel Angel, Amita Patnaik, Robert G. Maki, Bert O’Neil, James L. Abbruzzese, Ibiayi Dagogo-Jack, Siddhartha Devarakonda, et al. “Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.” In Journal of Clinical Oncology, Vol. 40, 2022.
       Link to Item
    • Subbiah, Vivek, Mark M. Awad, Adil Daud, Martin Gutierrez, Jessica Dreger McDermott, Sai-Hong Ignatius Ou, Tomoko Hirohashi, et al. “Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.” In Journal of Clinical Oncology, 39:TPS2671–TPS2671. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps2671.
       Full Text
    • Nixon, Andrew, Joyce Liu, Niya Xiong, Herbert I. Hurwitz, Jing Lyu, Yingmiao Liu, Mark Starr, et al. “Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial.” In Gynecologic Oncology, 162:S99–S99, 2021.
       Link to Item
    • Liu, Joyce F., Su-Chun Cheng, Robert M. Wenham, Andrea E Wahner Hendrickson, Deborah K. Armstrong, Nancy Chan, David E. Cohn, et al. “Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer.” In Molecular Cancer Therapeutics, 18:A074–A074. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1535-7163.targ-19-a074.
       Full Text
    • Monjazeb, Arta, Anita Giobbie-Hurder, Ana Lako, Mark Awad, Ryan Gentzler, Carrie Lee, Joleen Hubbard, et al. “A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021.” In Journal for Immunotherapy of Cancer, Vol. 7. BMC, 2019.
       Link to Item
    • Kent, C. L., D. Marin, D. Niedzwiecki, S. J. Stephens, E. Duffy, M. Malicki, J. Abbruzzese, et al. “Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 105:E238–39. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2014.
       Full Text
    • Stephens, S. J., B. Czito, X. Zhang, E. Duffy, M. Malicki, B. Pitcher, D. Niedzwiecki, et al. “Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S180–S180. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.07.056.
       Full Text
    • Moschos, S. J., Z. Eroglu, N. I. Khushalani, K. L. Kendra, G. Ansstas, G. K. In, P. Wang, et al. “NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).” In Ann Oncol, 29 Suppl 8:viii453, 2018. https://doi.org/10.1093/annonc/mdy289.024.
       Full Text  Link to Item
    • Turner, Megan C., Marcelo Cerullo, Mohamed Adam, Kevin N. Shah, Dan G. Blazer, James L. Abbruzzese, and Sabino Zani. “Adjuvant Chemotherapy Should Follow Pancreaticoduodenectomy for Pancreatic Adenocarcinoma, Despite Delays.” In Journal of the American College of Surgeons, 227:S169–S169. Ovid Technologies (Wolters Kluwer Health), 2018. https://doi.org/10.1016/j.jamcollsurg.2018.07.359.
       Full Text
    • Liu, Joyce F., William Thomas Barry, Robert Michael Wenham, Andrea Elisabeth Wahner Hendrickson, Deborah Kay Armstrong, Nancy Chan, David E. Cohn, et al. “A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).” In Journal of Clinical Oncology, 36:5519–5519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5519.
       Full Text
    • Palta, Manisha, Brian G. Czito, Eileen Duffy, Mary Malicki, Donna Niedzwiecki, James L. Abbruzzese, Hope Elizabeth Uronis, Gerard C. Blobe, Dan G. Blazer, and Christopher Willett. “A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.” In Journal of Clinical Oncology, 36:4121–4121. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4121.
       Full Text
    • Palta, M., B. Czito, J. Abbruzzese, H. Uronis, E. A. Duffy, D. T. Blazer, and C. G. Willett. “Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study.” In International Journal of Radiation Oncology Biology Physics, 96:S204–5, 2016.
       Link to Item
    • Lu, Weiqin, Yaying Yang, Xiaojie Wang, Yan Liu, Yongde Luo, Robert A. Wolff, James L. Abbruzzese, and Craig D. Logsdon. “Abstract 891: FGF21 prevents high fat diet-induced pancreatic cancer in mice expressing oncogenic Kras.” In Cancer Research, 75:891–891. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.am2015-891.
       Full Text
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
       Link to Item
    • Estrella, J., L. Li, A. Rashid, H. Wang, M. H. Katz, J. B. Fleming, and J. L. Abbruzzese. “Solid Pseudopapillary Neoplasm of the Pancreas: Clinicopathologic and Survival Analyses of 64 Cases from a Single Institution.” In Modern Pathology, 27:448A-449A, 2014.
       Link to Item
    • Katz, Matthew H. G., Huamin Wang, Jason B. Fleming, Charlotte C. Sun, Rosa F. Hwang, Robert A. Wolff, Gauri Varadhachary, et al. “Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.” In Ann Surg Oncol, 16:836–47, 2009. https://doi.org/10.1245/s10434-008-0295-2.
       Full Text  Link to Item
    • Abbruzzese, James L. “Highlights of the 2008 San Antonio Breast Cancer Symposium.” In Clin Adv Hematol Oncol, 7:39–41, 2009.
       Link to Item
    • Javle, M. M., X. Xie, W. Xia, Z. Li, H. Kuo, Y. Liu, Q. Ding, et al. “Pancreatic cancer targeted C-VISA-BikDD: DNA-liposome complex results in minimal toxicity in vivo.” In Molecular Cancer Therapeutics, 6:3482S-3482S, 2007.
       Link to Item
    • Li, Donghui, Keping Xie, Robert Wolff, and James L. Abbruzzese. “Pancreatic cancer.” In Lancet, 363:1049–57, 2004. https://doi.org/10.1016/S0140-6736(04)15841-8.
       Full Text  Link to Item
    • Xiong, Henry Q., James L. Abbruzzese, Hiroyasu Esumi, Tomoo Kosuge, Tadao Kakizoe, and Takashi Sugimura. “Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer.” In Jpn J Clin Oncol, 33:246–53, 2003. https://doi.org/10.1093/jjco/hyg047.
       Full Text  Link to Item
    • Abbruzzese, James L. “Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.” In Semin Oncol, 29:2–8, 2002. https://doi.org/10.1053/sonc.2002.37382.
       Full Text  Link to Item
    • Xiong, Henry Q., and James L. Abbruzzese. “Epidermal growth factor receptor-targeted therapy for pancreatic cancer.” In Semin Oncol, 29:31–37, 2002. https://doi.org/10.1053/sonc.2002.35645.
       Full Text  Link to Item
    • Abbruzzese, J. L. “Cancer: Introduction.” In Cancer, 95:907, 2002. https://doi.org/10.1002/cncr.10752.
       Full Text
    • Abbruzzese, James L. “New applications of gemcitabine and future directions in the management of pancreatic cancer.” In Cancer, 95:941–45, 2002. https://doi.org/10.1002/cncr.10753.
       Full Text  Link to Item
    • Abbruzzese, J. L., and H. Yamauchi. “Evolving concepts in chemotherapy and surgery for bilio-pancreatic cancer: Introduction.” In Seminars in Oncology, 29:1, 2002. https://doi.org/10.1053/sonc.2002.37370.
       Full Text
    • “Precancerous lesions of the digestive tract. The 18th Annual Symposium of the European Cancer Prevention Organization. Maastricht, The Netherlands. 12-14 October 2000. Abstracts.” In Eur J Cancer Prev, 9:443–63, 2000.
       Link to Item
    • Verschraegen, C. F., M. Vincent, J. L. Abbruzzese, D. Siegler, J. J. Kavanagh, E. Loyer, A. P. Kudelka, and E. Rubin. “Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.” In Ann N Y Acad Sci, 922:345–48, 2000. https://doi.org/10.1111/j.1749-6632.2000.tb07061.x.
       Full Text  Link to Item
    • Chiao, P. J., K. K. Hunt, A. M. Grau, A. Abramian, J. Fleming, W. Zhang, T. Breslin, J. L. Abbruzzese, and D. B. Evans. “Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.” In Ann N Y Acad Sci, 880:31–37, 1999. https://doi.org/10.1111/j.1749-6632.1999.tb09507.x.
       Full Text  Link to Item
    • Breslin, T. M., N. A. Janjan, J. E. Lee, P. W. Pisters, R. A. Wolff, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” In Front Biosci, 3:E193–203, 1998. https://doi.org/10.2741/a377.
       Full Text  Link to Item
    • “NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network.” In Oncology (Williston Park), 12:226–309, 1998.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.